

LJMU Research Online

Gjuladin-Hellon, T, Davies, IG, Penson, P and Amiri Baghbadorani, R

Effects of carbohydrate restricted diets on low density lipoprotein-cholesterol levels in overweight and obese adults: a systematic review and meta-analysis of large randomised controlled trials of at least 6 months

http://researchonline.ljmu.ac.uk/id/eprint/8898/

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Gjuladin-Hellon, T, Davies, IG, Penson, P and Amiri Baghbadorani, R (2018) Effects of carbohydrate restricted diets on low density lipoproteincholesterol levels in overweight and obese adults: a systematic review and meta-analysis of large randomised controlled trials of at least 6 months.

LJMU has developed LJMU Research Online for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk

http://researchonline.ljmu.ac.uk/

1 Article type: Special Article

2 Effects of carbohydrate restricted diets on low density lipoprotein-cholesterol levels in

- overweight and obese adults: a systematic review and meta-analysis of large randomised
 controlled trials of at least 6 months
- 5 Teuta Gjuladin-Hellon^{1,2}, Ian G. Davies^{1*}, Peter Penson³, Raziyeh Amiri Baghbadorani¹
- 6 ¹School of Sports Studies and Nutrition, Faculty of Education, Health and Community,
- 7 Liverpool John Moores University, Merseyside, UK. ²Faculty of Food Technology and
- 8 Nutrition, University of Tetovo, Macedonia.³ School of Pharmacy and Biomolecular Sciences,
- 9 Faculty of Science, Liverpool John Moores University, Merseyside, UK.
- 10 *Corresponding author: <u>i.g.davies@ljmu.ac.uk</u>, School of Sports Studies and Nutrition,
- 11 Faculty of Education, Health and Community, Liverpool John Moores University. IM Marsh
- 12 Campus, Barkhill Road, Liverpool UK, L17 6BD.
- 13 Abstract
- 14 Context
- 15 Carbohydrate restricted diets may increase low density lipoprotein-cholesterol and thereby
- 16 cardiovascular risk.
- 17 **Objective**
- 18 A systematic review and meta-analyses was conducted to compare the effects of very low, low
- 19 and moderate carbohydrate higher fat diets versus high-carbohydrate low-fat diets on low
- 20 density lipoprotein-cholesterol and other lipid markers in overweight/obese adults.
- 21 Data Sources
- 22 Medline, PubMed, Cochrane Central, and CINAHL Plus were searched to identify large
- 23 randomised controlled trials (n > 100) with duration ≥ 6 months.
- 24 Data Extraction
- Eight randomised controlled trials (n = 1633, 818 carbohydrate restricted, 815 low fat diet) were included.
- 27 Data Analysis
- Quality assessment and risk of bias, a random effects model, sensitivity and subgroup analysis
 based on the degree of carbohydrate restriction were performed using Cochrane Review
 Manager. Results were reported according to 'Preferred Reporting Items for Systematic
 Reviews and Meta-Analysis Protocol'.

32 **Results**

- 33 Carbohydrate restricted diets showed a none significant difference in low density lipoprotein-
- 34 cholesterol after 6, 12, and 24 months. While an overall pooled analysis statistically favoured
- 35 low-fat diets [0.07 mmol/L; 95% CI 0.02, 0.13; p = 0.009] this was clinically insignificant.
- 36 High density lipoprotein-cholesterol and plasma triglycerides at 6 and 12 months, favoured
- 37 carbohydrate restricted diets [0.08 mmol/L, 95% CI 0.06, 0.11; $p < 1x10^{-5}$ and -0.13 mmol/L,
- 38 95% CI -0.19, -0.08; $p < 1x10^{-5}$] respectively. These favourable changes were more marked in
- 39 the subgroup with very-low carbohydrate content (< 50 g/day) [0.12 mmol/L, 95% CI 0.10,
- 40 0.14; $p < 1x10^{-5}$ and -0.19 mmol/L, 95% CI -0.26, -0.12, p = 0.02] respectively.

41 Conclusions

42 Large randomised controlled trials of at least 6 months duration with carbohydrate restriction 43 appear superior in improving lipid markers when compared to low-fat diets. Dietary guidelines 44 should consider carbohydrate restriction as an alternative dietary strategy for the 45 prevention/management of dyslipidaemia for populations with cardiometabolic risk. 46

47 Key words: low carbohydrate diet, low density lipoprotein cholesterol, lipid profile,

- 48 cardiovascular disease, meta-analysis
- 49

50

51 Introduction

"All scientific work is incomplete – whether it be observational or experimental. All scientific
work is liable to be upset or modified by advancing knowledge. That does not confer upon us a
freedom to ignore the knowledge we already have, or to postpone the action that it appears to
demand at a given time".

56

Austin Bradford Hill

The galloping global and upward trend in obesity/overweight prevalence and the epidemics of 57 non-communicable diseases¹ is raising concern regarding the efficiency of existing dietary 58 recommendations. Questions on the strength of the evidence on which these recommendations 59 are based^{2,3} as well as the role of saturated fatty acids (SFA), polyunsaturated fatty acids 60 (PUFA), and refined carbohydrates in the on-set of cardiovascular disease (CVD) have 61 historically been and continue to be debated.^{4.9} Recently, an ample amount of evidence 62 suggests that carbohydrate restricted diets (CRDs) including low, moderate, and very low 63 carbohydrate ketogenic diets (LCD, MLCD, VLCD respectively) have the potential to improve 64 various metabolic pathways with the added beneficial effects in treatment of 65 overweight/obesity, and in amelioration of cardiometabolic risk markers.⁹⁻¹⁴ VLCD are often 66 interchangeable with the terminology, 'ketogenic diet' (KD). The underlying mechanism of a 67 KD is reduction in the levels of circulating insulin along with increased levels of glucagon due 68

69 to scarcity of dietary carbohydrates, leading to a reduction in lipogenesis and fat 70 accumulation.¹⁵⁻¹⁷ This results in an increased mobilization of fatty acids from adipocytes and 71 overproduction of ketone bodies, which are used as an alternative fuel to glucose by the extra-72 hepatic tissues such as the brain and the muscle.¹⁵⁻¹⁸ Ketone bodies also reduce the catabolism 73 of lean body mass, which in large explains the preservation of lean tissue observed during very 74 low carbohydrate dieting.^{12,19}

The main concern regarding CRDs, which are potentially high in total and SFA, is their 75 theoretically adverse effect on low density lipoprotein-cholesterol (LDL-C) levels and 76 presumably, CVD risk. Saturated fat per se is not associated with increased CVD risk, as 77 concluded in several recent meta-analyses and systematic reviews^{6,20,21} due, to some extent, to 78 the differential effects of saturated fat on LDL subclass concentrations. Namely, cholesterol-79 enriched large buoyant LDL particles (lbLDL) have shown to be less atherogenic, while small 80 dense (sdLDL) and medium sized LDL particles more strongly associate with CVD 81 outcomes.²²⁻²⁶ Data suggest that a shift towards lbLDL occurs among participants following a 82 CRD, resulting in a decreased CVD-risk, while the opposite occurs among those on high-83 carbohydrate diets.²⁷ However, the role of low-carbohydrate ketogenic diets in the long-term 84 management of obesity and cardiometabolic risk markers is not well established. Data from 85 recent systematic reviews and meta-analyses regarding LDL-C are very contradictory. While 86 some find an increased level,²⁸⁻³⁰ others report non-significant changes³¹ or decreased levels³² 87 of LDL-C in subjects following CRD compared to those on a low fat diets (LFD). 88

By Due to the lack of consensus on the effects of CRD on LDL-C between these findings, authors have been very cautious in making recommendations for or against them. This has also led to deepening the disagreement among experts² and further uncertainty for the public especially regarding the long-term effectiveness of CRDs, pointing towards the need to further reconsider and evaluate the existing scientific evidence. The lack of consensus could be partially assigned

to the heterogeneity of the CHO content in interventions as definitions of CRDs differ,¹⁴ and/or 94 in inclusion and exclusion criteria used during the selection procedures of performed meta-95 analyses. For example, some meta-analyses include trials of both healthy and diabetic 96 patients³² and many report only the pooled net effect of large and small trials without 97 stratification by duration of intervention or follow up.²⁸⁻³⁰ Small studies may overestimate 98 intervention effects, introduce higher heterogeneity and increase risk of selection bias³³⁻³⁶ 99 while larger studies are considered to have more power to detect differences in observed 100 outcomes and are more likely to generate conclusions that can be generalised³⁷. Based on these 101 limitations, Santos et al.³⁸ performed a meta-analysis of randomised controlled trials (RCTs) 102 103 with at least 100 overweight/obese healthy participants. This study reports an initial increase of 104 LDL-C in the period 0-6 months, followed by a significant decrease at 12 and 24 months, and 105 overall significantly favourable effect of the CRD on the main cardiometabolic risk markers. Though well designed and important, the limitation of this meta-analysis lies in the fact that 106 the final effects are compared to the baseline values with no comparison against LFDs. 107

In light of these shortcomings and contradictory findings, the aim of this systematic review and 108 109 meta-analysis is to compare the effects of CRD and LFD on LDL-C and other lipid markers in overweight/obese adults, using data obtained from large RCTs with at least 6 months' duration. 110 This research also pertains to suggest the choice of diet that would be most effective for 111 prevention and management of dyslipidaemia in population groups at higher risk of 112 cardiovascular disease (e.g. obesity, overweight, metabolic syndrome, type 2 diabetes) and to 113 contribute to the discussion about whether current dietary guidelines should be reconsidered 114 and adapted to the latest evidence. 115

116 Methods

117 This systematic review and meta-analysis is performed and reported according to the Preferred 118 Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement³⁹ (Appendix 119 S1) and the PICOS (Population, Intervention, Comparison, and Outcomes) (Table 1) criteria 120 were used to define the following research question: Do long-term carbohydrate restricted, 121 higher-fat diets have an adverse effect on LDL-C levels and presumably CVD risk among 122 overweight/obese adults?

123 Search methods

The following databases were searched for relevant RCTs published between January 1970 124 and June 2017 with no restriction on language: Medline (EBSCO), PubMed, Cochrane Central, 125 126 and CINAHL Plus. These databases were searched individually with advanced search 127 strategies using various combinations of filters and controlled vocabulary in relation to both 128 carbohydrate restricted diets and low fat diets in order to enhance precisions and sensitivity (Appendix 2. Furthermore, previous relevant meta-analyses, systematic reviews, and selected 129 randomised controlled trials were manually searched for studies that met the 130 inclusion/exclusion criteria. 131

132 Inclusion criteria and data abstraction

RCTs included in this research were required to compare the effects of carbohydrate restricted 133 diets (CRD) (defined as $\leq 45\%$ total energy intake (TEI) from CHO, including MLCD $\leq 45\%$ -134 >26% TEI or 130 – 225 g, LCD as 10 - <26% TEI or 50 – 130 g, and VLCD as <10% TEI or 135 < 50 g, and > 35% TEI from fat, fed ad libitum) versus a LFD (defined as $\le 35\%$ TEI from fat 136 and \geq 50% TEI from CHO, and restriction on total energy intake)^{40,41} with outcomes on 137 serum/plasma LDL-C and other lipid profile markers, namely total cholesterol (TC), high 138 139 density lipoprotein-cholesterol (HDL-C) and triglycerides (TG), published between 1970 and 140 June, 2017. Large randomised controlled trials with duration of at least six months and with at 141 least 100 randomised adult participants (18-65 years) at the start of the dietary intervention, 142 with a body mass index (BMI) > 25 kg/m² were included. The decision to include RCTs ≥ 6 143 months was based on the differential effects on LDL-C in shorter term versus longer term 144 studies and lack of comparison to low fat diets at this duration, i.e. compared to baseline, 145 LDL-C increases at 6 months but decreases at 12 and 24 months.³⁸

146 Exclusion criteria

147 To increase power, reduce heterogeneity, and selection bias, $^{33-35,37}$, trials with a study 148 population < 100 randomised participants were excluded. Trials with a specific pathology 149 rather than obesity (such as diabetes, cancer, kidney or coronary heart disease), altered 150 endocrinological state (such as pregnancy, lactation or menopause), trials with a duration < 6 151 months and trials which did not report standard deviation (SD) or 95% confidence intervals 152 (CI) were also excluded.

153 Data extraction and quality assessment

In order to minimise potential bias during selection procedure, the duplicates of full articles 154 retrieved for further assessment were independently read by two reviewers (T.G.H and R.A.B) 155 to make a consent decision for inclusion. From studies with more than two interventions, the 156 most suitable dietary interventions were chosen for comparison. The following data were 157 collected: title, first author, year of publication, country, design of RCT (parallel, cross-over, 158 factorial), blinding of participant and personnel (open, single, double), baseline characteristics 159 of study participants such as age, sex, BMI, and total number of randomised participants, 160 health status, and baseline LDL-C, HDL-C, TG and TC values, composition of diet, attrition, 161 handling of missing data and overall and subgroup mean difference in outcomes with measures 162 of variance (SD or 95% CI). The Cochrane Collaboration tool⁴² was used for assessing 163 164 methodological quality and risk of bias with the following categories: selection bias (random sequence generation, allocation concealment), performance bias (blinding of participants and personnel and blinding of the outcome assessment), reporting bias (selective outcome reporting), and other biases. Publication bias was assessed with funnel plots. Disagreements were resolved by discussion and by seeking the opinion of the third independent reviewer (I.G.D.), as required by the PRISMA statement.³⁹

170 Data synthesis and data analysis

Extracted data from eligible studies were first tabulated by outcome of interest and presented 171 in mmol/L; data expressed in mg/dL were converted into mmol/L by multiplying the values 172 with the factor 0.0259 for cholesterol and its fractions, and the factor 0.013 for conversion of 173 TG. In studies reporting mean values and 95% CI, the SD was calculated. Intervention effects 174 across trials were pooled to calculate weighted mean differences and the 95% CI for each 175 176 continuous outcome (LDL-C, HDL-C, TG, TC) between baseline and 6, 12 and 24 months of intervention duration. The CRD arm was also divided into two subgroups based on the CHO-177 content: very low-carbohydrate diet (VLCD) with < 10% CHO TEI (< 50 g CHO) and 178 moderate low-carbohydrate diet (MLCD) with 26-45% CHO TEI (130 - 225 g CHO).43 179 Subgroup analyses were performed when possible in order to explore the potential effect of 180 different CHO content on the primary and secondary outcome estimates. It is important to note 181 that studies classified as low carbohydrate diets (LCDs) (10 - < 26% CHO TEI (50 - 130 g 182 183 CHO)) which would fulfil the inclusion criteria were not identified. The Random Effects Model was used to account for heterogeneity in design and outcome variables, as the 184 heterogeneity is incorporated in the total weighted efficacy of treatment, allowing for a greater 185 variability of the estimate.⁴⁴ Heterogeneity and inconsistency (I²) was calculated with the 186 Cochran Q test. I^2 values > 50% and > 75% indicated moderate and high heterogeneity 187 respectively.⁴² In order to evaluate the relative influence on the pooled estimated effects, a 188 sensitivity analysis was conducted by excluding studies that had less than 70% completion 189

7

190 rate, studies with a very low-fat diet, studies that were performed on women only, and on those 191 with the lowest mean age of participants. For detecting the existence of publication bias and its 192 possible effect on the performed meta-analysis, funnel plots as the most common method were 193 used. All statistical analyses were performed using Review Manager (RevMan 5.3.5).

194 Results

195 Literature search

The flow of the study selection procedure which followed the literature search is summarised 196 in Figure 1. Potential relevant records (308) were identified during the search of the databases 197 and additional 17 were identified from screening of references. After initial screening and 198 duplicate removal 252 records remained, of which 205 were excluded on the bases of 199 200 interrogation of abstracts, and 47 full-text articles were retrieved for detailed review. Thirtynine full-text records did not fulfil the set inclusion criteria and, after their removal, 8 RCTs 201 remained eligible to be included in the meta-analysis. The reasons for exclusion of the 39 full-202 article trials are presented in Table 2⁴⁵⁻⁸³. Five trials⁴⁵⁻⁴⁹ did not include LDL-C as an outcome; 203 ten trials⁵⁰⁻⁵⁹ were performed on participants with Diabetes mellitus and/or CVD; eleven 204 trials⁶⁰⁻⁷⁰ had less than 100 randomised participants; three⁷¹⁻⁷³ had duration < 6 months; two 205 trials^{74,75} did not report on SD or 95% CI; seven trials⁷⁶⁻⁸² were irrelevant with inappropriate 206 intervention; and one trial⁸³ was dismissed based on high attrition rate and high risk of bias. 207

208 Study and participant characteristics

The main characteristics of the eight published articles eligible for meta-analysis are summarised in Table 3⁸⁴⁻⁹¹. All eight RCTs were open and parallel group trials with no possibility for blinding of participants due to the polarity of diets. Intervention duration ranged from 6 to 24 months. Most of the trials offered some form of supportive dietary sessions and

professional contact and participants were encouraged to engage and maintain a certain level of 213 physical activity. However, none reported any record of the level of physical activity. Trials 214 were conducted on both sexes with a higher proportion of female participants, except for the 215 study by Gardner et al.⁸⁸ which was performed only on women. The mean age and BMI of 216 participants varied from 28.2 - 51.5 years, and $31.4 - 36.1 \text{ kg/m}^2$ respectively. All 8 trials^{84.91} 217 with a total of 1633 participants (n = 818 on CRD, n = 815 on LFD) reported 6 months follow 218 219 up; 5 trials with a total of 1010 participants (n = 505 on CRD, n = 505 on LFD) reported 12 months outcome measures^{84,86,87,89,90} and 2 studies with a total of 715 (n = 357 on CRD, n = 220 358 on LFD) reported data for 24 months.^{86,91} According to the CHO content, the CRD 221 222 intervention was divided into two subgroups: VLCD and MLCD (Table 3). The VLCDsubgroup consisted of four trials: three trials^{86,88,90} followed the Atkins diet (Dr. Atkins New 223 Diet Revolution, 1998)⁹², defined as < 20 g/d of CHO for the first three months, with a gradual 224 increase of 5 g/d after the third month up to 50 g/d CHO, while in one trial⁸⁴ the CHO intake 225 was restricted to < 40 g of CHO daily. The other 4 trials^{85,87,89,91} restricted the CHO 226 consumption to about 35-40% of the total daily energy, making up the MLCD subgroup. CRD 227 interventions were ad libitum in all trials regarding energy intake, but some studies reported a 228 spontaneous reduction of energy intake.^{87,88,90} LFD interventions permitted 50-65% of energy 229 from CHO and 20 - < 35% of energy deriving from fat across all trials, except for the trial of 230 Gardner *et al.*⁸⁸ with a very low fat (< 10%) high CHO (70%) intervention (Ornish) diet.⁹³ 231

Diet compliance was measured via three 24 h dietary recalls^{84,87,88,91} or 7-day food diaries.^{86,89,90} In the study of Due *et al.*⁸⁵ dietary intake and compliance was assessed by fat biopsy, while food was available from a custom made supermarket for the purpose of the trial with supervised shopping. Attrition rate showed large variation, with dropout rates ranging from 12-44%. All studies had applied Intention-to-treat analysis for the missing data. (Table 3). Reported baseline mean levels of LDL-C, HDL-C, TG, and TC varied across trials and intervention, but were well balanced in both the CRD and LFD arm of intervention in each study (Table 4^{84-91}).

LDL-C concentrations were directly measured except in the trials of Bazzano *et al.*⁸⁴ and Due et al.⁸⁵ where it was calculated using the Friedewald formula.⁹⁴ In the study of Klemsdal *et al.*⁸⁹ the assessment of LDL-C was not clearly stated. Three studies evaluated additional lipid profile markers that are of interest to the primary outcome: changes in LDL-peak density (g/L) reported by Morgan *et al.*⁹⁰, apolipoprotein-B concentration in the trial of Klemsdal *et al.*,⁸⁹ and concentration of the very low density lipoprotein cholesterol (VLDL-C) fraction in the study of Foster *et al.*⁸⁶

247 Quality assessment and risk of bias

The quality and the risk of bias (%) across all included studies were assessed using the 248 Cochrane Risk of Bias Tool and are presented in Figures 2 & 3⁸⁴⁻⁹¹. Three studies did not 249 clearly report on the sequence generation⁸⁹⁻⁹¹ and allocation concealment^{86,89,90} used. Blinding 250 of participants was impossible due to the nature of the trial. In addition, there was no blinding 251 of the outcome assessors reported, but considering the fact that all outcomes are objective, it is 252 unlikely that this has influenced the results of the RCTs. There was no evidence of selective 253 reporting and five trials⁸⁴⁻⁸⁸ showed low risk of attrition bias. Four studies^{86,89-91} were judged to 254 255 have a low risk of bias and no study received an overall score of 'high' in any assessed risk of 256 bias category.

257 Meta-analyses

258 Effects of CRD and LFD on LDL-Cholesterol levels

Results from the primary meta-analysis regarding the mean difference of LDL-C concentration between CRD and LFD intervention at 6, 12, and 24 months (compared to baseline) are

presented in Figure 4⁸⁴⁻⁹¹ & Table S1. Although participants on the CRD intervention 261 experienced a greater increase in LDL-C compared to the LFD, these changes are statistically 262 non-significant regardless of intervention duration [6 months: 0.08 mmol/L; 95% CI -0.01, 263 0.18; P = 0.08], [12 months: 0.04 mmol/L; 95% CI -0.04, 0.12; P = 0.37] and [24 months: 0.10 264 mmol/L; 95% CI -0.01, 0.21; P = 0.06]. However, analysis of the global pooled effect between 265 CRD and LFD interventions on LDL-C levels shows a significant weighted mean difference in 266 favour of the LFD [0.07 mmol/L; 95% CI 0.02, 0.13; P = 0.009]. Significant (moderate) 267 heterogeneity ($I^2 = 58\%$; P = 0.009) for the estimated difference of LDL-C between both diets 268 was observed only at 6 months. Sensitivity analysis (exclusion of studies one by one) was 269 carried out to identify the possible studies that could explain this heterogeneity. After 270 exclusion of the study of Foster et al.,⁸⁶ which had the highest weight effect, the heterogeneity 271 considerably decreased ($I^2 = 28\%$, P = 0.22), but did not significantly change the weighted 272 mean difference of LDL-C (P = 0.25). However, exclusion of the study of Due *et al.*,⁸⁵ did not 273 change the heterogeneity, but resulted with a statistically significant mean difference of LDL-C 274 at 6 months in favour of the LFD ($I^2 = 58\%$, P = 0.04). This is possibly because it is the 275 smallest study and/or has the lowest mean age of participants of 29.8 (Table 3). 276

Subgroup analyses were performed to explore the possible influence of the CHO-content of the 277 CRD intervention on LDL-C levels compared to the LFD-interventions. The very low 278 carbohydrate subgroup (VLCD) with < 10% CHO TEI (Figure 5^{84,86,88,90} & Table S2) and the 279 moderate carbohydrate subgroup (MLCD) with 35–45% CHO TEI (Figure 6^{85,87,89,91} & Table 280 S3) did not cause any significant difference of LDL-C compared to the LFD regardless of 281 duration of intervention. Both CRD-interventions, the VLCD and the MLCD, resulted with an 282 overall non-significant mean change of LDL-C compared to the LFD-intervention and values 283 were similar to the primary meta-analysis [for VLCD: 0.07 mmol/L; 95% CI -0.05, 0.18; 284 P=0.27 and for the MLCD: 0.05 mmol/L; 95% CI -0.02, 0.12; P=0.16]. 285

286 *Effects of CRD and LFD on HDL-C and Triglycerides levels*

The pooled global mean differences for HDL-C [HDL-C: 0.08 mmol/L, 95% CI 0.06, 0.11; P 287 $< 1x10^{-5}$] (Figure 7⁸⁴⁻⁹¹ & Table S1) and TG [-0.13 mmol/L, 95% CI -0.19, -0.08; P $< 1x10^{-5}$] 288 (Figure 8⁸⁴⁻⁹¹ & Table S1) showed an overall more favourable total effect of the CRD 289 intervention. However, the mean differences for both parameters were significant at 6 months 290 [HDL-C: 0.09 mmol/L, 95% CI 0.06, 0.12; P < 1x10⁻⁵ and TG: -0.18 mmol/L, 95% CI -0.25, -291 0.11; $P < 1x10^{-5}$] and 12 months [HDL-C: 0.09 mmol/L, 95% CI 0.02, 0.15; P = 0.008 and 292 TG: -0.11 mmol/L, 95% CI -0.18, -0.03; P = 0.005], but non-significant at 24 months [HDL-C: 293 0.05 mmol/L, 95% CI -0.00, 0.11; P = 0.06] and [TG: 0.01 mmol/L, 95% CI -0.12, 0.13; 294 P=0.93]. High heterogeneity of 74% was observed for HDL-C at 12 months, which was 295 considerably decreased after removal of the trial of Frisch et al.⁸⁷ without affecting the 296 significance of the weighted mean difference ($I^2 = 45\%$; P < 1x10⁻⁴). 297

The VLCD (Figure 9^{84,86,88,90} & Table S2) showed a greater increase of HDL-C compared to 298 the LFD throughout the entire observed period [for 6 months: 0.13 mmol/L, 95% CI 0.09, 299 0.16; P = 1×10^{-5} ; for 12 months: 0.13 mmol/L, 95% CI 0.09, 0.17; P = 1×10^{-5} and for 24 300 months: 0.08 mmol/L, 95% CI 0.02, 0.14; P = 0.01]. Regarding TG concentration, the VLCD 301 was more favourable at 6 months [-0.24 mmol/L, 95% CI -0.32, -0.16; $P = 1 \times 10^{-5}$] and 12 302 months [-0.16 mmol/L, 95% CI -0.25, -0.06; P = 0.002] of the diet intervention, levelling its 303 effect with the LFD group at 24 months [0.02 mmol/L, 95% CI -0.16, 0.02; P = 0.82] (Figure 304 10^{84,86,88,90} & Table S2). Compared to the LFD, the MLCD showed more favourable effects 305 regarding HDL-C and TG only for the initial period of 6 months of intervention duration 306 307 respectively [HDL-C: 0.06 mmol/L, 95% CI 0.02, 0.10; P = 0.002] and [TG: -0.09 mmol/L, 95% CI -0.18, 0.0; P = 0.05] (Figures $11^{85,87,89,91}$, $12^{85,87,89,91}$, & Table S3). Based on the 308 overall total effect, the subgroup analyses showed that the VLCD was more effective than the 309

- 310 MLCD for HDL-C and TG, suggesting that the amount of CHO in CRD interventions plays an
- important role and its effect depends on the duration of intervention (Table S2 & S3).
- 312 Effects of CRD and LFD on Total Cholesterol levels

TC as an outcome was reported only in six studies^{84-87,89,91}, which did not permit a meaningful 313 subgroup analyses based on the CHO content of CRD interventions. The primary meta-314 analysis for the estimated mean difference of total cholesterol level (Figure 13)^{84-87,89,91} & 315 Table S1 revealed a negligible, but nevertheless more favourable significant effect of the CRD 316 in the initial 6 months period [-0.01 mmol/L, 95% CI -0.01, -0.00; P = 0.02]. It is worth noting 317 that though the estimated mean difference at 12 months was identical to the 6 month value, it 318 showed to be statistically insignificant [-0.01 mmol/L, 95% CI -0.04, 0.3; P=0.78]. Both diets 319 seemed to show no effect on total cholesterol level after 24 months of intervention [-0.00 320 mmol/L, 95% CI -0.01, 0.00; P = 0.66]. The combined total effect of all studies was 321 statistically in favour of the CRD intervention but clinically meaningless [-0.00 mmol/L, 95%] 322 CI -0.01, 0.00; P = 0.002]. 323

324 Effects of CRD and LFD on lipid markers not included in the meta-analysis

Results of the LDL-peak density in the trial of Morgan *et al.*⁹⁰ showed that after six months of 325 intervention, this variable decreased within both dietary groups included in this RCT. 326 However, the decrease of the LDL-peak density indicating an increase in LDL particle size 327 was significantly greater than the control (no intervention group) only among participants on 328 the VLCD diet. No significant changes of apolipoprotein-B after 12 months were found within 329 and between dietary intervention groups in the trial of Klemsdal et al.⁸⁹ Decreases in VLDL-C 330 levels reported by Foster et al.⁸⁶ were significantly greater in the CRD than in the LFD group 331 332 at 6 months [LFD: -0.12 mmol/L; 95% CI -0.17, -0.08 vs CRD: -0.23 mmol/L; 95% CI -0.27, -333 0.19; P < 0.001] and 12 months [LFD: -0.09 mmol/L; 95% CI -0.16, -0.02 vs CRD: -0.21

mmol/L; 95% CI -0.27, -0.19; P = 0.009], but non-significant differences were found at 24
months [LFD: -0.05 mmol/L; 95% CI -0.12, -0.004 vs CRD: -0.05 mmol/L; 95%CI -0.12, 0.0007; P = 0.99]

337 Funnel Plots and Publication Bias

Upon visual inspection, all three funnel plots (Figures S1-3) appeared to be approximately symmetrical, therefore no evidence of publication bias was found. However, the small number of studies included in this meta-analysis means that the funnel plots must be interpreted very cautiously, and the possibility of publication bias cannot be ruled out.

342 Discussion

The present meta-analysis of large randomised controlled trials with duration of at least six 343 months compared the effects of CRDs with different CHO content versus LFD on LDL-C 344 levels as a primary outcome, and HDL-C, TG and TC as secondary outcomes. The primary 345 meta-analysis of the effects of CRDs and LFD on LDL-C levels showed an overall significant 346 weighted mean difference in favour of the LFD despite the non-significant changes at 6, 12 347 and 24 months of intervention duration (Figure 4). However, the subgroup analysis of LDL-C 348 levels based on the CHO content of the CRD arm (Figures 5 & 6), showed non-significant net 349 changes for both the VLCD and the MLCD diets throughout the whole observed period (6, 12 350 and 24 months). Further, participants on CRDs experienced negligible changes of TC levels 351 after 6 months (Figure 13) and more favourable changes on HDL-C and TG at 6 and 12 352 months (Figures 7 & 8) resulting in overall more favourable net effects of CRDs compared to 353 the LFD regarding these lipid markers. The comparison between VLCD and MLCD subgroups 354 revealed the VLCD showed a marked increase and decrease of HDL-C and TG respectively 355 356 (Figures 9-12). It is worth noting, however, that the analyses with a follow up of 24 months 357 included only two trials.

The more favourable changes in several lipid parameters (HDL-C and TG) and non-significant 358 changes of LDL-C in both the VLCD and MLCD subgroup analysis, despite the slight global 359 increase in LDL-C, support the view that carbohydrate restriction, especially the VLCD, is 360 more effective in improving investigated CVD risk markers. The presented findings with 361 regard to LDL-C, HDL-C and TG weighted mean changes are relatively consistent with the 362 findings of several other meta-analyses,^{28,32,95} all concluding that CRDs are at least as 363 beneficial as the LFD and thus proposing CRDs as an alternative tool for treatment of 364 metabolic risk and obesity. These findings are also in line with the most recent meta-analyses 365 by Mansoor et al.²⁹ and Lu et al.³⁰ investigating the effects of a CRD vs LFD on cardiovascular 366 risk markers. While the Lu et al.³⁰ study showed an increase in LDL-C of 0.11 mmol/L (95% 367 368 CI 0.205, 0.026) with the CRD, the authors emphasised the beneficial HDL-C raising effect of the CRD of 0.066 mmol/L (95% CI, 0.10, 0.033) equating to a 7.45% reduction in relative risk 369 of CVD. However, Mansoor et al.²⁹ found an overall increase in LDL-C level of 0.16 mmol/L 370 (95% CI 0.003, 0.33) with the CRD and highlighted its possible detrimental effect on CVD, 371 stating this may outweigh the benefits of the increased HDL-C and decreased TG levels 372 observed. The results of the present study show the inverse; the overall increase in LDL-C of 373 0.07 mmol/L (95% CI 0.02, 0.13) with the CRD in the primary meta-analysis equates to a 374 1.54% relative risk reduction in cardiovascular events.⁹⁶ With HDL-C the pooled increase of 375 0.08 mmol/L (95% CI 0.06, 0.11) reduces relative risk by 4.6% (using the latest evidence from 376 the European Atherosclerosis Society).⁹⁷ Furthermore, the lack of significant difference for 377 LDL-C at 6, 12 and 24 months and in the VLCD and the MLCD-subgroup analysis supports a 378 negated risk of CVD from LDL-C. These differences are presumably due to the different 379 380 inclusion/exclusion criteria during the selection process between the current and the two previous meta-analyses.^{29,30} 381

Targeting LDL-C has been a conventional strategy in prevention and treatment of CVD and 382 reduction of mortality rate^{98,99} using statins that inhibit the 3-hydroxy-3-methylglutaryl-CoA 383 (HMG-CoA) reductase activity which decreases hepatic cholesterol production and 384 upregulation of the LDL-receptor.¹⁰⁰ However, the reduction of CVD risk accomplished with 385 this strategy, as it has been reported in several clinical trials,^{101,102} is no more than 30%. The 386 main limitations of this strategy lies in the observed atherosclerotic complications among 387 participants even after reaching acceptable LDL-C goals¹⁰³ which is indicative of the presence 388 of other risk factors beyond LDL-C that should be considered. 389

Extensive evidence has shown that parameters which take into consideration the role of 390 triglyceride-rich remnant lipoproteins or non-HDL-C as an indicator of cholesterol within all 391 the apolipoprotein-B (apo-B) particles (including LDL, VLDL, Lp(a), and to some extent, 392 intermediate-density lipoprotein, chylomicrons, and chylomicron remnants) are superior to 393 LDL-C in quantifying the atherogenic properties of lipoproteins.^{104,105} In that context, non-394 HDL-C, TG, and the TC/HDL-C ratio are more strongly associated with increased CVD risk 395 than LDL-C, as depicted in several prospective studies such as: the Lipid Research Clinics 396 397 Program Longitudinal Follow-up Study with over 19 years of follow-up of CVD risk and mortality rate¹⁰⁶; the Framingham Offspring Study¹⁰⁷; the 11 year follow up of the EPIC 398 (European Prospective Investigation Into Cancer and Nutrition) Norfolk prospective 399 population study.¹⁰⁸ This study quantified the risk associated with these lipid parameters for 400 each level of LDL-C, from low (< 2.59 mmol/L (100 mg/dL)) to high (> 4.14 mmol/L (160 401 mg/dL)) in non-fasting samples.¹⁰⁸ In addition, analysis of pooled data from nine RCTs on 402 subjects with coronary artery disease undergoing serial intravascular ultrasonography, reports 403 that the lower TC/HDL-C ratio lowers the risk of major adverse cardiovascular events and 404 lower coronary atheroma progression rates.¹⁰⁹ The above evidence points to the residual risk 405 when LDL-C lowering treatments have failed to reduce cardiovascular events, and recent 406

407 review articles suggest focus should turn to drug or diet treatment other than LDL-C 408 lowering.^{110,111} In the light of these consistent findings, it has been proposed that non–HDL-C 409 be routinely used as a cost effective target in prevention and treatment of CVD risk.^{109,112} 410 Thus, when assessing the CVD risk of this negligible increase in total LDL-C concentration 411 produced by the CRDs, the marked increase in HDL-C in parallel to a marked decrease of TG 412 with an overall neutral effect on TC, as found in the current meta-analysis, must be 413 acknowledged.

The strategy to target LDL-C concentration as a primary CVD risk marker also disregards the 414 heterogeneity of LDL-particle number (LDL-P) and size as a function of atherogenecity, an 415 important indicator particularly when LDL-C is not elevated. Namely, sdLDL particles 416 (phenotype B) are more strongly associated with CVD outcomes than the lbLDL particles 417 (phenotype A).^{24,25,113,114} sdLDL particles are characterised by a longer plasma residence time, 418 which results in higher particle oxidation and glycation, further reduction in size and increased 419 accumulation within arterial intima.^{26,113} Increased concentrations of sdLDL particles produced 420 by delipidated larger atherogenic VLDL and large LDL, and direct de novo hepatic production, 421 correlate with increasing TG and decreasing HDL-C levels.²⁵ Hence, increased TG 422 concentration and higher TG/HDL-C ratios are superior predictors of an increasingly 423 atherogenic LDL phenotype (phenotype B) than LDL-C, as it indicates higher levels of 424 remnant lipoprotein particle cholesterol along with higher non-HDL-C and LDL density.^{114,115} 425

Further, recent evidence suggests that apo-B and LDL-P concentration are superior to LDL-C and non-HDL-C for assessment of CVD risk,¹¹⁶ particularly among subjects with metabolic syndrome and insulin resistance, as found in the Framingham Heart Study¹¹⁷ and in the cohort of the Quebec Cardiovascular Study.¹¹⁸ The concordance/discordance analysis of plasma apo-B and LDL-P in two large retrospective cohorts shows that the discordance of LDL-P > apo-B is associated with sdLDL particle size, insulin resistance and increased systemic

inflammation.¹¹⁹ Evidence regarding the effect of CRDs on LDL-P size and apo-B in the 432 published literature is scarce, which was also revealed during this study. In the presented 433 systematic review, decreased LDL-peak density were reported by Morgan et al.⁹⁰ only among 434 participants following the Atkins diet when compared to the control, while decreased VLDL-C 435 concentrations were found by Foster et al.⁸⁶ These findings, though in favour of the VLCD, are 436 not yet sufficient to make a meaningful judgement, as more large RCTs with longer duration 437 438 are necessary in order to compare and critically discuss these variables. However, the results of the RCT conducted by Sharman et al.¹²⁰ show that a short-term (6 week) hypoenergetic VLCD 439 (< 10% CHO TEI) led to improvement of cardiometabolic risk factors: increased mean and 440 peak LDL-P size along with fasting serum TG, TG/HDL-C ratio, postprandial lipaemia, serum 441 glucose and insulin resistance in overweight men.¹²⁰ Similar findings, namely, increase in peak 442 LDL-P size, a shift towards lbLDL in participants who started with a predominance of sdLDL-443 P, and overall improvement of CVD and diabetic risk markers after a 6 week KD-intervention 444 in normolipidaemic men with normal body weight¹²¹ and after 12 weeks in subjects with 445 atherogenic dyslipidaemia¹¹ were found. 446

The main argument against low-carbohydrate high-fat diets is the potential adverse effect on 447 the TC and LDL-C levels as a result of a relative or absolute increase in dietary SFA due to 448 CHO restriction,^{4,7,14} although the magnitude of the effect shows variations in constellation to 449 the specific diet quality and individual susceptibility.^{5,122,123} Macronutrient dietary content 450 451 with SFA intake is almost unavoidable, because these fatty acids are present in all fatcontaining foods (dairy products, meats, egg yolk, and in some vegetable fats and oils). SFA 452 are non-uniform compounds and their metabolic effects and potency to alter plasma lipids and 453 lipoproteins depend on the composition of SFA in their structure. As an illustration, evidence 454 suggests that palmitate increases LDL-C and the LDL-C/HDL-C ratio and may enhance 455 thrombogenesis, while stearate does not affect these lipoproteins; laurate increases LDL-C and 456

HDL-C levels, and decreases TG concentrations and the TC/HDL ratio.^{124,125} Despite the 457 persisting belief, saturated fats per se are not robustly linked with increased all-cause mortality, 458 CVD risk, ischemic stroke or type 2 diabetes, as concluded in several recent meta-analyses and 459 systematic reviews.^{6,20,21} Though associated with increased LDL-C concentration, higher SFA 460 intake mainly increases the less atherogenic lbLDL,^{126,127} confirmed also in a RCT among 461 participants assigned to a high-fat (46% fat) compared to a low-fat (24% fat) diet for 6 462 weeks.¹²⁸ Conversely, partial replacement of dietary SFA with CHO, particularly with fructose 463 and sucrose, results with production of elevated sdLDL-P and overall unfavourable effects on 464 the lipid profile, impaired glucose tolerance and insulin resistance^{14,122,129,130}. In other words, 465 by shifting sdLDL-P towards lbLDL (phenotype B to A), dietary SFA seem to be protective 466 against the effect of CHO. 467

There is very little data available on the effects of different amounts of SFA on 468 cardiometabolic risk factors in participants following a CRD. Krauss et al.⁷¹ found initial 469 reduction in TG, apo-B, LDL-C, sdLDL and TC/HDL cholesterol and increased LDL peak 470 diameter in subjects undergoing low/moderate carbohydrate intake (26% CHO) with different 471 472 amounts of SFA (7-9% and 15%) during weight-loss. However, after subsequent weight loss and weight stabilisation, authors reported that improvements of these parameters were 473 significantly greater with the 54% CHO diet. Nevertheless, this clearly confirms that a 474 moderate short-term CHO restriction still has the potential to improve atherogenic 475 dyslipidaemia, even in the absence of weight loss or in the presence of SFA, while the LFD 476 seems to require weight loss for its effective improvement, as argued by Feinman & Volek.²⁷ 477 Hence, based on the above supporting evidence, the fear that CRDs might have adverse health 478 effects due to increased consumption of saturated fats in particular, would appear to be 479 groundless. This is also pointed out in several reviews.^{7,9,14} 480

Dietary guidelines do not only shift the population away from SFA and towards increased 481 CHO intake, but also encourage replacement of SFA with PUFA, without stating any specific 482 type of PUFA. The pooled effects of a meta-analysis of RCTs¹³¹ and 11 cohort studies¹³² 483 indeed provide evidence that substituting SFA with PUFA significantly reduces CVD events. 484 However, substitution of SFA and trans-fats with n-6 PUFA without increasing n-3 PUFA, 485 decreases HDL-C and increases oxidised LDL, resulting with an increased risk of all-cause 486 mortality (mainly cancer, CVD and coronary heart disease), as reported in the meta-analysis of 487 Ramsden et al.¹³³ Thus, research and concerns should be more focused on the dietary 488 guidelines that suggest replacing SFA with a specific dietary PUFA, as the beneficial claims 489 regarding PUFAs in general may be even harmful as recently suggested.^{14,122,130} The 490 macronutrient content of both CRDs and the LFDs in the RCTs included in this meta-analysis 491 492 is not clearly described as they are performed on free living adults, fed ad libitum. Nevertheless, the findings of this meta-analysis in light of the presented to date available 493 evidence demonstrate lower non-HDL-C, and lower TG/HDL-C and TC/HDL-C ratios, 494 supporting the claim that CRDs, especially the VLCD arm are more effective in the long-term 495 reduction of CVD risk markers. Moreover, findings also suggest that the LFD in fact presents a 496 potential risk as it contributes towards increased atherogenic dyslipidaemia. 497

498

499 Strengths and Limitations of the study

This is the first meta-analysis that compares the long-term effects between CRD vs LFD on LDL-C levels in adults. Its strength lies in the inclusion of large RCTs (n > 100 of randomised participants) as they have more power to detect intervention effects and are more likely to generate conclusions that can be generalised. Further, the duration of follow-up was 6-24 months, which enabled comparison of intervention effects at three points (6, 12 and 24

months) compared to the baseline values. Separating the CRD arm into VLCD and MLCD 505 allowed the estimation, when possible, of the long-term effects of CRDs with different CHO 506 content on LDL-C and other lipid parameters. However, this study has several limitations. The 507 trials were performed on free living participants; hence the macronutrient content of both the 508 CRD and the LFD arms remains unknown, making it impossible to separately investigate the 509 effects of the macronutrient groups (CHO, lipids and proteins) and/or their subgroups on the 510 511 outcomes of interest. Diet compliance was assessed via food diaries and 24 h diet recalls which may result in biased association due to inaccurate reporting in the trials^{134,135} and subsequent 512 discrepancies in effect estimates in the meta-analysis¹³⁶ which cannot be detected via the 513 Cochrane Risk of Bias Tool. 514

Attrition rates between the CRD and the LFD were relatively similar, although adherence was 515 decreasing after 6 months regardless of the type of intervention. This to some extend might 516 explain the more distinct changes of all parameters during the first six months of intervention 517 as subjects tend to return to their baseline dietary habits, which was outlined in the long-term 518 RCTs included in this research.⁸⁶⁻⁸⁸ This has also been confirmed in the three-year follow-up of 519 a RCT⁵¹, that found non-significant differences in carbohydrate consumption after 36 months 520 between participants following either a CRD or a LFD. Hence, behavioural treatments to 521 522 increase long-term compliance appear to be as important as the composition of the diet in prevention and treatment of CVD risk. Lastly, increased LDL-C may be an artefact due to the 523 overestimation in trials where it is calculated by the Friedewald formula⁹⁴; in cases when the 524 TG level falls, as it happens amongst subjects on CRDs, even if TC and HDL-C remain 525 unchanged, calculated LDL-C shows an increased level.¹³⁷ 526

527 Conclusions and Implications for future research

Undoubtedly, the overall 'picture' of this study demonstrates that carbohydrate restriction, 528 especially the VLCD, shows superiority over the LFD in improving cardiometabolic risk 529 markers due to the superior effects on HDL-C and TG with only negligible effect on LDL-C 530 and no effect on TC. These favourable outcomes from the CRD, should be considered for the 531 prevention and management of dyslipidaemia in population groups at higher risk of 532 cardiovascular disease (e.g. obesity/overweight, metabolic syndrome, prediabetes and type 2 533 534 diabetes). The results of the presented meta-analysis suggest that the current guidelines should consider the latest evidence and carbohydrate restriction should be included as an alternative 535 for individuals with increased cardiometabolic risk. In general, the number of well-designed 536 large RCTs that would compare the long-term effects between the CRD and LFD on 537 cardiometabolic risk markers in overweight and obese adults is very small. Large and long-538 term RCTs with emphasis on psychosomatic experiences of patients and their views on 539 motivation to undergo diet-change, focus on the quality and quantity of dietary macronutrients, 540 more accurate assessment of the lipid profile (LDL and HDL subfractions and particle number, 541 concentration of apolipoproteins) and inflammatory markers are warranted. In addition, 542 metabolomics analysis linking to the hallmark metabolite concentrations would provide an 543 insight on a molecular level regarding inter-individual variation in response to the same dietary 544 exposure and understanding of contradictions in data findings. Considering the epidemics of 545 obesity and obesity related comorbidities, new nutritional approaches and more focused 546 innovative interventions are needed in order to achieve lasting behavioural changes among 547 population groups at higher cardiometabolic risk (obesity/overweight, metabolic syndrome, 548 prediabetes, type 2 diabetes, and CVD). 549

550

551 Acknowledgments

- 552 I.G.D. and T.G-H conceptualised the original idea and constructed the literature search
- 553 strategy. T.GH, and R.A.B assessed identified studies in duplicate with final review by I.G.D.
- 554 T.G-H and PP performed the meta-analysis and assessment of bias respectively. T.G-H wrote
- 555 the manuscript with critical feedback by I.G.D. All authors contributed to editing the
- 556 manuscript. The above work received no funding and the authors declare no conflict of
- 557 interest. We would like to acknowledge Ms. Jackie Fealey, Academic Liaison Librarian at
- 558 Liverpool John Moores University, and Dr Nicola Harman, Research Associate, Clinical Trials
- 559 Research Centre, University of Liverpool for their assistance with the database search,
- 560 accessing electronic resources, and referencing.

561 Supporting Information

- 562 Appendix S1 PRISMA checklist
- 563 Appendix S2 Search strategy

Table S1 Weighted mean difference of LDL-C, HDL-C, TG, and TC between CRD and LFD

- at 6, 12 and 24 months compared to baseline (mmol/L)
- Table S2 Weighted mean difference of LDL-C, HDL-C and TG between VLCD and LFD at 6,
- 567 12 and 24 months compared to baseline (mmol/L)
- Table S3 Weighted mean difference of LDL-C, HDL-C and TG between MLCD and LFD at 6,
- 569 12 and 24 months compared to baseline (mmol/L)
- Figure S1 Funnel plot of the mean LDL-C differences (mmol/L) between CRD and LFD
 across trials (n=8)
- 572 Figure S2 Funnel plot of the mean HDL-C differences (mmol/L) between CRD and LFD 573 across trials (n=8)
- Figure S3 Funnel plot of the mean TG differences (mmol/L) between CRD and LFD acrosstrials (n=8)
- 576

577 References

- 578 1. Fiscal policies for diet and prevention of noncommunicable diseases: technical meeting 579 report, 5-6 May 2015, Geneva, Switzerland. World Health Organization.
- Hite AH, Feinman RD, Guzman GE, Satin M, Schoenfeld PA, Wood RJ. In the face of contradictory evidence: report of the Dietary Guidelines for Americans Committee. *Nutrition.* 2010;26(10):915-924.
- 5833.Scholl J. Traditional dietary recommendations for the prevention of cardiovascular disease:584do they meet the needs of our patients? *Cholesterol.* 2012;2012:367898.
- 5854.Ravnskov U. The questionable role of saturated and polyunsaturated fatty acids in
cardiovascular disease. J Clin Epidemiol. 1998;51(6):443-460.
- Ravnskov U, DiNicolantonio JJ, Harcombe Z, Kummerow FA, Okuyama H, Worm N. The
 questionable benefits of exchanging saturated fat with polyunsaturated fat. *Mayo Clin Proc.* 2014;89(4):451-453.

500	C	Citization DNA Con Onthe ED Maria and NA Incorporation of a standard standard
590	6.	Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Meta-analysis of prospective cohort studies
591		evaluating the association of saturated fat with cardiovascular disease. Am J Clin Nutr.
592	_	2010;91(3):535-546.
593	7.	Harcombe Z, Baker JS, Davies B. Evidence from prospective cohort studies did not support
594		the introduction of dietary fat guidelines in 1977 and 1983: a systematic review. Br J Sports
595	0	Med. 2017;51(24):1737-1742.
596	8.	Mann J, Morenga LT, McLean R, et al. Dietary guidelines on trial: the charges are not
597	0	evidence based. <i>Lancet.</i> 2016;388(10047):851-853.
598	9.	Harcombe Z. Dietary fat guidelines have no evidence base: where next for public health
599 600	10	nutritional advice? <i>Br J Sports Med.</i> 2017;51(10):769-774.
600	10.	Meckling KA, O'Sullivan C, Saari D. Comparison of a low-fat diet to a low-carbohydrate diet
601		on weight loss, body composition, and risk factors for diabetes and cardiovascular disease in free living overweight more and women (Clin Enderstine) Match 2004/80(6):2717, 2722
602 603	11	free-living, overweight men and women. <i>J Clin Endocrinol Metab.</i> 2004;89(6):2717-2723.
603 604	11.	Volek JS, Phinney SD, Forsythe CE, et al. Carbohydrate restriction has a more favorable
604 605	12.	impact on the metabolic syndrome than a low fat diet. <i>Lipids</i> . 2009;44(4):297-309. Paoli A, Rubini A, Volek JS, Grimaldi KA. Beyond weight loss: a review of the therapeutic uses
606	12.	of very-low-carbohydrate (ketogenic) diets. <i>Eur J Clin Nutr.</i> 2013;67(8):789-796.
607	13.	Hu T, Bazzano LA. The low-carbohydrate diet and cardiovascular risk factors: evidence from
608	15.	epidemiologic studies. Nutr Metab Cardiovasc Dis. 2014;24(4):337-343.
609	14.	Noakes TD, Windt J. Evidence that supports the prescription of low-carbohydrate high-fat
610	14.	diets: a narrative review. Br J Sports Med. 2017;51(2):133-139.
611	15.	Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill GF, Jr. Brain metabolism
612	15.	during fasting. J Clin Invest. 1967;46(10):1589-1595.
613	16.	Fukao T, Lopaschuk GD, Mitchell GA. Pathways and control of ketone body metabolism: on
614	10.	the fringe of lipid biochemistry. <i>Prostaglandins Leukot Essent Fatty Acids</i> . 2004;70(3):243-
615		251.
616	17.	Manninen AH. Metabolic effects of the very-low-carbohydrate diets: misunderstood
617		"villains" of human metabolism. J Int Soc Sports Nutr. 2004;1(2):7-11.
618	18.	Cahill GF, Jr. Fuel metabolism in starvation. Annu Rev Nutr. 2006;26:1-22.
619	19.	Paoli A, Canato M, Toniolo L, et al. [The ketogenic diet: an underappreciated therapeutic
620		option?]. Clin Ter. 2011;162(5):e145-153.
621	20.	Chowdhury R, Warnakula S, Kunutsor S, et al. Association of dietary, circulating, and
622		supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern
623		Med. 2014;160(6):398-406.
624	21.	de Souza RJ, Mente A, Maroleanu A, et al. Intake of saturated and trans unsaturated fatty
625		acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic
626		review and meta-analysis of observational studies. BMJ. 2015;351:h3978.
627	22.	Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by
628		nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting
629		incident cardiovascular disease in women. <i>Circulation</i> . 2009;119(7):931-939.
630	23.	Williams PT, Zhao XQ, Marcovina SM, Otvos JD, Brown BG, Krauss RM. Comparison of four
631		methods of analysis of lipoprotein particle subfractions for their association with
632		angiographic progression of coronary artery disease. Atherosclerosis. 2014;233(2):713-720.
633	24.	Krauss RM. All low-density lipoprotein particles are not created equal. Arterioscler Thromb
634		Vasc Biol. 2014;34(5):959-961.
635	25.	Diffenderfer MR, Schaefer EJ. The composition and metabolism of large and small LDL. Curr
636		<i>Opin Lipidol.</i> 2014;25(3):221-226.
637	26.	Thongtang N, Diffenderfer MR, Ooi EMM, et al. Metabolism and proteomics of large and
638		small dense LDL in combined hyperlipidemia: effects of rosuvastatin. J Lipid Res.
639		2017;58(7):1315-1324.

640	27.	Feinman RD, Volek JS. Low carbohydrate diets improve atherogenic dyslipidemia even in the
641	20	absence of weight loss. Nutr Metab (Lond). 2006;3:24.
642	28.	Bueno NB, de Melo IS, de Oliveira SL, da Rocha Ataide T. Very-low-carbohydrate ketogenic
643		diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials.
644	20	Br J Nutr. 2013;110(7):1178-1187.
645	29.	Mansoor N, Vinknes KJ, Veierod MB, Retterstol K. Effects of low-carbohydrate diets v. low-
646		fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised
647 648	20	controlled trials. <i>Br J Nutr.</i> 2016;115(3):466-479. Lu M, Wan Y, Yang B, Huggins CE, Li D. Effects of low-fat compared with high-fat diet on
648 649	30.	cardiometabolic indicators in people with overweight and obesity without overt metabolic
650		disturbance: a systematic review and meta-analysis of randomised controlled trials. Br J
651		Nutr. 2017:1-13.
652	31.	Naude CE, Schoonees A, Senekal M, Young T, Garner P, Volmink J. Low carbohydrate versus
653	51.	isoenergetic balanced diets for reducing weight and cardiovascular risk: a systematic review
654		and meta-analysis. <i>PLoS One.</i> 2014;9(7):e100652.
655	32.	Hu T, Mills KT, Yao L, et al. Effects of low-carbohydrate diets versus low-fat diets on
656	52.	metabolic risk factors: a meta-analysis of randomized controlled clinical trials. Am J
657		Epidemiol. 2012;176 Suppl 7:S44-54.
658	33.	Zhang Z, Xu X, Ni H. Small studies may overestimate the effect sizes in critical care meta-
659		analyses: a meta-epidemiological study. <i>Crit Care.</i> 2013;17(1):R2.
660	34.	IntHout J, Ioannidis JP, Borm GF, Goeman JJ. Small studies are more heterogeneous than
661		large ones: a meta-meta-analysis. J Clin Epidemiol. 2015;68(8):860-869.
662	35.	Barnard ND, Willett WC, Ding EL. The Misuse of Meta-analysis in Nutrition Research. JAMA.
663		2017;318(15):1435-1436.
664	36.	Kendall JM. Designing a research project: randomised controlled trials and their principles.
665		Emerg Med J. 2003;20(2):164-168.
666	37.	Biau DJ, Kerneis S, Porcher R. Statistics in brief: the importance of sample size in the planning
667		and interpretation of medical research. Clin Orthop Relat Res. 2008;466(9):2282-2288.
668	38.	Santos FL, Esteves SS, da Costa Pereira A, Yancy WS, Jr., Nunes JP. Systematic review and
669		meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk
670		factors. Obes Rev. 2012;13(11):1048-1066.
671	39.	Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic
672		reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
673	40.	Trumbo P, Schlicker S, Yates AA, Poos M, Food, Nutrition Board of the Institute of Medicine
674		TNA. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol,
675		protein and amino acids. J Am Diet Assoc. 2002;102(11):1621-1630.
676	41.	Hite AH, Berkowitz VG, Berkowitz K. Low-carbohydrate diet review: shifting the paradigm.
677		Nutr Clin Pract. 2011;26(3):300-308.
678	42.	Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing
679	40	risk of bias in randomised trials. <i>BMJ</i> . 2011;343:d5928.
680	43.	Feinman RD, Pogozelski WK, Astrup A, et al. Dietary carbohydrate restriction as the first
681		approach in diabetes management: critical review and evidence base. <i>Nutrition.</i>
682		2015;31(1):1-13.
683	44. 45.	DerSimonian R, Laird N. Meta-analysis in clinical trials. <i>Control Clin Trials</i> . 1986;7(3):177-188.
684 685	43.	Hu T, Yao L, Reynolds K, et al. The Effects of a Low-Carbohydrate Diet vs. a Low-Fat Diet on Novel Cardiovascular Risk Factors: A Randomized Controlled Trial. <i>Nutrients.</i> 2015;7(9):7978-
685 686		7994.
687	46.	McManus K, Antinoro L, Sacks F. A randomized controlled trial of a moderate-fat, low-energy
688	40.	diet compared with a low fat, low-energy diet for weight loss in overweight adults. Int J Obes
689		Relat Metab Disord. 2001;25(10):1503-1511.

600		
690	47.	Viegener BJ, Perri MG, Nezu AM, Renjilian DA, Mckelvey WF, Schein RL. Effects of an
691		Intermittent, Low-Fat, Low-Calorie Diet in the Behavioral Treatment of Obesity. <i>Behav Ther</i> .
692		1990;21(4):499-509.
693	48.	Zelicha HS, D.; Shelef, I.; Gepner, Y. et al. Changes of renal sinus fat and renal parenchymal
694		fat during an 18-month randomized weight loss trial. <i>Clinical nutrition (no pagination), 2017.</i>
695		2017;Date of Publication: July 26.
696	49.	Blüher M, Rudich A, Klöting N, et al. Two Patterns of Adipokine and Other Biomarker
697		Dynamics in a Long-Term Weight Loss Intervention. <i>Diabetes Care</i> . 2012;35(2):342-349.
698	50.	Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, Mediterranean,
699		or low-fat diet. <i>N Engl J Med.</i> 2008;359(3):229-241.
700	51.	Cardillo S, Seshadri P, Iqbal N. The effects of a low-carbohydrate versus low-fat diet on
701		adipocytokines in severely obese adults: three-year follow-up of a randomized trial. Eur Rev
702		Med Pharmacol Sci. 2006;10(3):99-106.
703	52.	Tsai AG, Glick HA, Shera D, Stern L, Samaha FF. Cost-effectiveness of a low-carbohydrate diet
704		and a standard diet in severe obesity. Obes Res. 2005;13(10):1834-1840.
705	53.	Stern L, Iqbal N, Seshadri P, et al. The effects of low-carbohydrate versus conventional
706		weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann
707		Intern Med. 2004;140(10):778-785.
708	54.	Dyson PA, Beatty S, Matthews DR. A low-carbohydrate diet is more effective in reducing
709		body weight than healthy eating in both diabetic and non-diabetic subjects. Diabet Med.
710		2007;24(12):1430-1435.
711	55.	Samaha FF, Iqbal N, Seshadri P, et al. A low-carbohydrate as compared with a low-fat diet in
712		severe obesity. N Engl J Med. 2003;348(21):2074-2081.
713	56.	Yancy WS, Jr., Westman EC, McDuffie JR, et al. A randomized trial of a low-carbohydrate diet
714		vs orlistat plus a low-fat diet for weight loss. Arch Intern Med. 2010;170(2):136-145.
715	57.	Hu TY, L.; Reynolds, K.; Niu, T. et al. The effects of a low-carbohydrate diet on appetite: a
716		randomized controlled trial. Nutr Metab Cardiovasc Dis. 2016;26(6):476-488.
717	58.	Turer CBB, I. H.; Edelman, D. E.; Yancy, W. S. Low HDL predicts differential blood pressure
718		effects from two weight-loss approaches: a secondary analysis of blood pressure from a
719		randomized, clinical weight-loss trial. <i>Diabetes Obes Metab.</i> 2012;14(4):375-378.
720	59.	Qi QD, R.; Schwarzfuchs, D.; Leitersdorf, E.; Shpitzen, S.; Li, Y.; Wu, H.; Champagne, C. M.;
721		Hu, F. B.; Stampfer, M. J.; Bray, G. A.; Sacks, F. M.; Shai, I.; Qi, L. CETP genotype and changes
722		in lipid levels in response to weight-loss diet intervention in the POUNDS LOST and DIRECT
723		randomized trials1. J Lipid Res. 2015;56(3):713-721.
724	60.	Lim SS, Noakes M, Keogh JB, Clifton PM. Long-term effects of a low carbohydrate, low fat or
725	00.	high unsaturated fat diet compared to a no-intervention control. Nutr Metab Cardiovasc Dis.
726		2010;20(8):599-607.
727	61.	Das SK, Gilhooly CH, Golden JK, et al. Long-term effects of 2 energy-restricted diets differing
728	01.	in glycemic load on dietary adherence, body composition, and metabolism in CALERIE: a 1-y
729		randomized controlled trial. <i>Am J Clin Nutr.</i> 2007;85(4):1023-1030.
730	62.	Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity.
731	02.	N Engl J Med. 2003;348(21):2082-2090.
732	63.	Seshadri P, Iqbal N, Stern L, et al. A randomized study comparing the effects of a low-
733	05.	carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein
734		levels in patients with severe obesity. <i>Am J Med.</i> 2004;117(6):398-405.
735	64.	Brehm BJ, Seeley RJ, Daniels SR, D'Alessio DA. A randomized trial comparing a very low
736	04.	carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular
730		risk factors in healthy women. J Clin Endocrinol Metab. 2003;88(4):1617-1623.
737	65.	Keogh JB, Brinkworth GD, Clifton PM. Effects of weight loss on a low-carbohydrate diet on
738	03.	flow-mediated dilatation, adhesion molecules and adiponectin. <i>Br J Nutr.</i> 2007;98(4):852-
739 740		859.
740		

741	66.	Ebbeling CB, Leidig MM, Feldman HA, Lovesky MM, Ludwig DS. Effects of a low-glycemic
742		load vs low-fat diet in obese young adults: a randomized trial. JAMA. 2007;297(19):2092-
743		2102.
744	67.	Bradley U, Spence M, Courtney CH, et al. Low-fat versus low-carbohydrate weight reduction
745		diets: effects on weight loss, insulin resistance, and cardiovascular risk: a randomized control
746		trial. <i>Diabetes.</i> 2009;58(12):2741-2748.
747	68.	Tay J, Brinkworth GD, Noakes M, Keogh J, Clifton PM. Metabolic effects of weight loss on a
748		very-low-carbohydrate diet compared with an isocaloric high-carbohydrate diet in
749		abdominally obese subjects. J Am Coll Cardiol. 2008;51(1):59-67.
750	69.	Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins,
751		Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a
752		randomized trial. JAMA. 2005;293(1):43-53.
753	70.	Leichtle ABH, C.; Ceglarek, U.; Shai, I. et al. Effects of a 2-y dietary weight-loss intervention
754		on cholesterol metabolism in moderately obese men. <i>Am J Clin Nutr.</i> 2011;94(5):1189-1195.
755	71.	Krauss RM, Blanche PJ, Rawlings RS, Fernstrom HS, Williams PT. Separate effects of reduced
756		carbohydrate intake and weight loss on atherogenic dyslipidemia. Am J Clin Nutr.
757		2006;83(5):1025-1031; quiz 1205.
758	72.	Petersen M, Taylor MA, Saris WH, et al. Randomized, multi-center trial of two hypo-
759		energetic diets in obese subjects: high- versus low-fat content. Int J Obes (Lond).
760		2006;30(3):552-560.
761	73.	Harvie M, Wright C, Pegington M, et al. The effect of intermittent energy and carbohydrate
762		restriction v. daily energy restriction on weight loss and metabolic disease risk markers in
763		overweight women. Br J Nutr. 2013;110(8):1534-1547.
764	74.	Yancy WS, Jr., Olsen MK, Guyton JR, Bakst RP, Westman EC. A low-carbohydrate, ketogenic
765		diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial.
766		Ann Intern Med. 2004;140(10):769-777.
767	75.	Westman EC, Yancy WS, Jr., Olsen MK, Dudley T, Guyton JR. Effect of a low-carbohydrate,
768		ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses. Int J
769		Cardiol. 2006;110(2):212-216.
770	76.	Jenkins DJ, Kendall CW, Nguyen TH, et al. Effect on hematologic risk factors for coronary
771		heart disease of a cholesterol reducing diet. <i>Eur J Clin Nutr.</i> 2007;61(4):483-492.
772	77.	Merra G, Gratteri S, De Lorenzo A, et al. Effects of very-low-calorie diet on body
773		composition, metabolic state, and genes expression: a randomized double-blind placebo-
774		controlled trial. Eur Rev Med Pharmacol Sci. 2017;21(2):329-345.
775	78.	Juanola-Falgarona MI-J, N.; Salas-Salvadó, J.; Rabassa-Soler, A.; Bulló, M. Design and
776		methods of the GLYNDIET study; assessing the role of glycemic index on weight loss and
777		metabolic risk markers. Nutricion hospitalaria. 2013;28(2):382-390.
778	79.	Wan YW, F.; Yuan, J.; Li, J.et al. Effects of Macronutrient Distribution on Weight and Related
779		Cardiometabolic Profile in Healthy Non-Obese Chinese: A 6-month, Randomized Controlled-
780		Feeding Trial. EBioMedicine. 2017;22:200-207.
781	80.	Le T, Flatt SW, Natarajan L, et al. Effects of Diet Composition and Insulin Resistance Status on
782		Plasma Lipid Levels in a Weight Loss Intervention in Women. J. Am. Heart Assoc. 2016;5(1).
783	81.	Juanola-Falgarona MS-S, J.; Ibarrola-Jurado, N.; Rabassa-Soler, A.et al. Effect of the glycemic
784		index of the diet on weight loss, modulation of satiety, inflammation, and other metabolic
785		risk factors: a randomized controlled trial. <i>Am J Clin Nutr.</i> 2014;100(1):27-35.
786	82.	Rock CLF, S. W.; Pakiz, B.; Quintana, E. L.; Heath, D. D.; Rana, B. K.; Natarajan, L. Effects of
787		diet composition on weight loss, metabolic factors and biomarkers in a 1-year weight loss
788		intervention in obese women examined by baseline insulin resistance status. <i>Metab. Clin.</i>
789		<i>Exp.</i> 2016;65(11):1605-1613.

 83. Brinkworth GD, Noakes M, Buckley JD, Keogh JB, Clifton PM. Long-term effects of a carbohydrate weight loss diet compared with an isocaloric low-fat diet after 12 mc Nutr. 2009;90(1):23-32. 	•
793 84. Bazzano LA, Hu T, Reynolds K, et al. Effects of low-carbohydrate and low-fat diets:	а
randomized trial. <i>Ann Intern Med.</i> 2014;161(5):309-318.	4
795 85. Due A, Larsen TM, Mu H, Hermansen K, Stender S, Astrup A. Comparison of 3 ad lik	pitum
796 diets for weight-loss maintenance, risk of cardiovascular disease, and diabetes: a 6	
797 randomized, controlled trial. <i>Am J Clin Nutr.</i> 2008;88(5):1232-1241.	
798 86. Foster GD, Wyatt HR, Hill JO, et al. Weight and metabolic outcomes after 2 years o	n a low-
 carbohydrate versus low-fat diet: a randomized trial. <i>Ann Intern Med.</i> 2010;153(3) 87. Frisch S, Zittermann A, Berthold HK, et al. A randomized controlled trial on the efficiency of the second second	:147-157.
801 carbohydrate-reduced or fat-reduced diets in patients attending a telemedically gu	•
802 weight loss program. <i>Cardiovasc Diabetol.</i> 2009;8:36.	nueu
803 88. Gardner CD, Kiazand A, Alhassan S, et al. Comparison of the Atkins, Zone, Ornish, a	ndIEADN
804 diets for change in weight and related risk factors among overweight premenopau	
805 women: the A TO Z Weight Loss Study: a randomized trial. <i>JAMA</i> . 2007;297(9):969-	
806 89. Klemsdal TO, Holme I, Nerland H, Pedersen TR, Tonstad S. Effects of a low glycemic	
807 versus a low-fat diet in subjects with and without the metabolic syndrome. <i>Nutr M</i>	
808 <i>Cardiovasc Dis.</i> 2010;20(3):195-201.	elub
809 90. Morgan LM, Griffin BA, Millward DJ, et al. Comparison of the effects of four comm	ercially
810 available weight-loss programmes on lipid-based cardiovascular risk factors. Public	Health
811 <i>Nutr.</i> 2009;12(6):799-807.	
812 91. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different	
813 compositions of fat, protein, and carbohydrates. <i>N Engl J Med.</i> 2009;360(9):859-87	'3.
814 92. Atkins R. <i>Dr Atkins' New Diet Revolution</i> . South Dakota: Vermillion; 1998.	
815 93. Ornish D. <i>Eat more, weigh less.</i> New York: Harper Collins; 2001.	
816 94. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-de	nsity
817 lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. C	lin Chem.
818 1972;18(6):499-502.	
819 95. Schwingshackl L, Hoffmann G. Comparison of effects of long-term low-fat vs high-f	
820 blood lipid levels in overweight or obese patients: a systematic review and meta-a	nalysis. J
821 <i>Acad Nutr Diet.</i> 2013;113(12):1640-1661.	
822 96. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosc	
823 cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studie	
824 consensus statement from the European Atherosclerosis Society Consensus Panel.	Eur Heart
825 <i>J.</i> 2017;38(32):2459-2472.	
826 97. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and hi	
827 lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence a	and
828 guidance for management. <i>Eur Heart J.</i> 2011;32(11):1345-1361.	
98. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics2015	update: a
830 report from the American Heart Association. <i>Circulation</i> . 2015;131(4):e29-322.	
99. Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to g	genes to
832 statins. <i>Cell</i> . 2015;161(1):161-172.	
833 100. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA re	ductase.
833100.Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA re834Science. 2001;292(5519):1160-1164.	
 833 100. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA re 834 Science. 2001;292(5519):1160-1164. 835 101. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering t 	reatment:
 833 100. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA re 834 Science. 2001;292(5519):1160-1164. 835 101. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering t 836 prospective meta-analysis of data from 90,056 participants in 14 randomised trials 	reatment:
 100. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA re <i>Science.</i> 2001;292(5519):1160-1164. 101. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering t prospective meta-analysis of data from 90,056 participants in 14 randomised trials <i>Lancet.</i> 2005;366(9493):1267-1278. 	reatment: of statins.
 833 100. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA re 834 Science. 2001;292(5519):1160-1164. 835 101. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering t 836 prospective meta-analysis of data from 90,056 participants in 14 randomised trials 	reatment: of statins. romes

841 842	103.	Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. <i>J</i> Lipid Res. 2002;43(9):1363-1379.
843	104.	Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density
844	104.	lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am
845		Coll Cardiol. 2008;51(7):724-730.
846	105.	Miller M, Ginsberg HN, Schaefer EJ. Relative atherogenicity and predictive value of non-high-
847		density lipoprotein cholesterol for coronary heart disease. Am J Cardiol. 2008;101(7):1003-
848		1008.
849	106.	Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a
850		predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161(11):1413-1419.
851	107.	Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for
852		prediction of coronary heart disease in men and women. <i>JAMA</i> . 2007;298(7):776-785.
853	108.	Arsenault BJ, Rana JS, Stroes ES, et al. Beyond low-density lipoprotein cholesterol: respective
854		contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total
855		cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in
856	4.00	apparently healthy men and women. <i>J Am Coll Cardiol</i> . 2009;55(1):35-41.
857	109.	Elshazly MB, Nicholls SJ, Nissen SE, et al. Implications of Total to High-Density Lipoprotein
858		Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma
859 860	110.	Progression and Cardiovascular Events. <i>Am J Cardiol.</i> 2016;118(5):647-655. Hermans MP, Valensi P. Elevated triglycerides and low high-density lipoprotein cholesterol
861	110.	level as marker of very high risk in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes.
862		2018;25(2):118-129.
863	111.	Averna M, Stroes E, lipid alterations beyond LDLewg. How to assess and manage
864		cardiovascular risk associated with lipid alterations beyond LDL. Atheroscler Suppl.
865		2017;26:16-24.
866	112.	Robinson JG. Are you targeting non-high-density lipoprotein cholesterol? J Am Coll Cardiol.
867		2009;55(1):42-44.
868	113.	Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low-density
869		lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy,
870		middle-aged men from the general population. <i>Circulation</i> . 2005;112(5):651-657.
871	114.	Krauss RM, Siri PW. Metabolic abnormalities: triglyceride and low-density lipoprotein.
872		Endocrinol Metab Clin North Am. 2004;33(2):405-415.
873	115.	Quispe R, Manalac RJ, Faridi KF, et al. Relationship of the triglyceride to high-density
874 975		lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large
875 876	116.	Database of Lipids-4 (VLDL-4) study. <i>Atherosclerosis</i> . 2015;242(1):243-250. Sniderman AD, Toth PP, Thanassoulis G, Furberg CD. An evidence-based analysis of the
870	110.	National Lipid Association recommendations concerning non-HDL-C and apoB. J Clin Lipidol.
878		2016;10(5):1248-1258.
879	117.	Kathiresan S, Otvos JD, Sullivan LM, et al. Increased small low-density lipoprotein particle
880		number: a prominent feature of the metabolic syndrome in the Framingham Heart Study.
881		<i>Circulation</i> . 2006;113(1):20-29.
882	118.	Sniderman AD, St-Pierre AC, Cantin B, Dagenais GR, Despres JP, Lamarche B.
883		Concordance/discordance between plasma apolipoprotein B levels and the cholesterol
884		indexes of atherosclerotic risk. Am J Cardiol. 2003;91(10):1173-1177.
885	119.	Varvel SA, Dayspring TD, Edmonds Y, et al. Discordance between apolipoprotein B and low-
886		density lipoprotein particle number is associated with insulin resistance in clinical practice. J
887		Clin Lipidol. 2015;9(2):247-255.
888	120.	Sharman MJ, Gomez AL, Kraemer WJ, Volek JS. Very low-carbohydrate and low-fat diets
889		affect fasting lipids and postprandial lipemia differently in overweight men. J Nutr.
890		2004;134(4):880-885.

891	121.	Sharman MJ, Kraemer WJ, Love DM, et al. A ketogenic diet favorably affects serum
892		biomarkers for cardiovascular disease in normal-weight men. J Nutr. 2002;132(7):1879-1885.
893	122.	DiNicolantonio JJ, Lucan SC, O'Keefe JH. The Evidence for Saturated Fat and for Sugar
894		Related to Coronary Heart Disease. Prog Cardiovasc Dis. 2016;58(5):464-472.
895	123.	Ruiz-Nunez B, Dijck-Brouwer DA, Muskiet FA. The relation of saturated fatty acids with low-
896		grade inflammation and cardiovascular disease. J Nutr Biochem. 2016;36:1-20.
897	124.	Mensink RP. Effects of Saturated Fatty Acids on Serum Lipids and Lipoproteins: A Systematic
898		Review and Regression Analysis. Geneva: World Health Organization;2016.
899	125.	Ramsden CE, Faurot KR, Carrera-Bastos P, Cordain L, De Lorgeril M, Sperling LS. Dietary fat
900		quality and coronary heart disease prevention: a unified theory based on evolutionary,
901		historical, global, and modern perspectives. Curr Treat Options Cardiovasc Med.
902		2009;11(4):289-301.
903	126.	Mangravite LM, Chiu S, Wojnoonski K, Rawlings RS, Bergeron N, Krauss RM. Changes in
904		atherogenic dyslipidemia induced by carbohydrate restriction in men are dependent on
905		dietary protein source. J Nutr. 2011;141(12):2180-2185.
906	127.	Faghihnia N, Mangravite LM, Chiu S, Bergeron N, Krauss RM. Effects of dietary saturated fat
907		on LDL subclasses and apolipoprotein CIII in men. Eur J Clin Nutr. 2012;66(11):1229-1233.
908	128.	Dreon DM, Fernstrom HA, Campos H, Blanche P, Williams PT, Krauss RM. Change in dietary
909		saturated fat intake is correlated with change in mass of large low-density-lipoprotein
910		particles in men. <i>Am J Clin Nutr.</i> 1998;67(5):828-836.
911	129.	Gerber PA, Berneis K. Regulation of low-density lipoprotein subfractions by carbohydrates.
912		Curr Opin Clin Nutr Metab Care. 2012;15(4):381-385.
913	130.	DiNicolantonio JJ. The cardiometabolic consequences of replacing saturated fats with
914	2001	carbohydrates or Omega-6 polyunsaturated fats: Do the dietary guidelines have it wrong?
915		Open Heart. 2014;1(1):e000032.
916	131.	Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing
917	191.	polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of
918		randomized controlled trials. <i>PLoS Med.</i> 2010;7(3):e1000252.
919	132.	Jakobsen MU, O'Reilly EJ, Heitmann BL, et al. Major types of dietary fat and risk of coronary
920	192.	heart disease: a pooled analysis of 11 cohort studies. <i>Am J Clin Nutr.</i> 2009;89(5):1425-1432.
921	133.	Ramsden CE, Hibbeln JR, Majchrzak SF, Davis JM. n-6 fatty acid-specific and mixed
922	1001	polyunsaturate dietary interventions have different effects on CHD risk: a meta-analysis of
923		randomised controlled trials. <i>Br J Nutr.</i> 2010;104(11):1586-1600.
924	134.	Samuel-Hodge CD, Fernandez LM, Henriquez-Roldan CF, Johnston LF, Keyserling TC. A
925	104.	comparison of self-reported energy intake with total energy expenditure estimated by
926		accelerometer and basal metabolic rate in African-American women with type 2 diabetes.
927		Diabetes Care. 2004;27(3):663-669.
928	135.	Hu FB. Obesity Epidemiology. Oxford University Press, New York; 2008.
929	136.	LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-
930	150.	analyses and subsequent large randomized, controlled trials. N Engl J Med. 1997;337(8):536-
931		542.
932	137.	Sniderman AD, Blank D, Zakarian R, Bergeron J, Frohlich J. Triglycerides and small dense LDL:
932 933	137.	the twin Achilles heels of the Friedewald formula. <i>Clin Biochem</i> . 2003;36(7):499-504.
934	138.	Blüher MR, A.; Klöting, N.; Golan, R. et al. Two Patterns of Adipokine and Other Biomarker
934 935	130.	Dynamics in a Long-Term Weight Loss Intervention. <i>Diabetes Care</i> . 2012;35(2):342-349.
222		שיומווונש ווו מ בטווצ-דפוווו איפוצות בטש וותפו יפותוטוו. <i>שומשפופש כמופ</i> . 2012,55(2).342-349.
936		
937		

938

Parameter	Inclusion criteria				
Population	Overweight/obese adult population (18-65) no restriction for sex				
Intervention	Carbohydrate restricted diets				
Comparison	Intervention vs Low-fat high-carbohydrate diet				
Outcome: Primary	Low density lipoprotein-cholesterol				
Secondary	High density lipoprotein-cholesterol, triglycerides, total cholesterol				
Setting	Randomised controlled trials with at least 100 randomised				
	participants and duration of at least 6 months				

Table 1: PICOS criteria for inclusion of studies

Table 2: Reasons	for exclusion	of full-text trial	ls (n = 39)
------------------	---------------	--------------------	-------------

Reason for exclusion	Authors
No LDL-C reported	Hu et al(2015) ⁴⁵ McManus et al(2001) ⁴⁶ Viegener et al(1990) ⁴⁷
	Zelicha et $al(2017)^{48}$ Blüher et $al(2012)^{138}$
D. mellitus and/or CVD	Shai et al (2008) ⁵⁰ Cardillo et al (2006) ⁵¹ Tsai et al (2005) ⁵² Stern
	<i>et al</i> $(2004)^{53}$ Dyson <i>et al</i> $(2007)^{54}$ Samaha <i>et al</i> $(2003)^{55}$ Yancy <i>et</i>
	<i>al</i> (2010) ⁵⁶ Hu <i>et al</i> (2016) ⁵⁷ Turer <i>et al</i> (2012) ⁵⁸ Qi <i>et al</i> (2015) ⁵⁹
<100 participants on start	Lim <i>et al</i> $(2010)^{60}$ Das <i>et al</i> $(2007)^{61}$ Foster <i>et al</i> $(2003)^{62}$ Seshadri
	<i>et al</i> $(2004)^{63}$ Brehm <i>et al</i> $(2003)^{64}$ Keogh <i>et al</i> $(2007)^{65}$ Ebbeling <i>et</i>
	$al (2007)^{66}$ Bradley <i>et al</i> (2009) ⁶⁷ Tay <i>et al</i> (2008) ⁶⁸ Dansinger <i>et al</i>
	$(2005)^{69}$ Leichtle <i>et al</i> $(2011)^{70}$
Short duration (<6 months)	Krauss <i>et al</i> $(2006)^{71}$ Petersen <i>et al</i> $(2006)^{72}$ Harvie <i>et al</i> $(2013)^{73}$
No SD / 95% CI reported	Yancy et al (2004) ⁷⁴ Westman et al (2006) ⁷⁵
Inappropriate intervention, irrelevant	Jenkins et al (2007) ⁷⁶ Merra et al (2017) ⁷⁷ Juanola-Falgarona et al
outcomes	(2013) ⁷⁸ Wan et al (2017) ⁷⁹ Le et al (2016) ⁸⁰ Juanola-Falgarona et
	$al (2014)^{81}$ Rock <i>et al</i> (2016)^{82}
High risk of bias, high dropout rate	Brinkworth <i>et al</i> $(2009)^{83}$

LDL-C, low density lipoprotein-cholesterol; CVD, cardiovascular disease; SD, standard deviation; CI, confidence intervals.

Author Country	Number CRD /	Mean Age	BMI	Duration (months)	Intervention	Intervention	Completed %	Missing data
·	LFD	Sex			CRD	LFD	CRD/LFD	
Bazzano <i>et</i> <i>al</i> (2014) ⁸⁴ * USA	75/73	50 Both	35.4	12	<40 g/d CHO, ad libitum*	55% of energy from CHO, <30% fat	88/79	ITT analysis
Due <i>et al</i> (2008) ⁸⁵ ** Denmark	52/48	28.2 Both	31.4	6	<45% energy from CHO, 35-45% from fat, >20% of MUFA**	20-30% energy from fat, 50-55% energy from CHO	56/73	ITT analysis
Foster <i>et al</i> (2010) ⁸⁶ * USA	153/154	45.5 Both	36.1	24	Atkins 20 g/d CHO, after 3 months gradual increase of CHO of 5 g/d, ad libitum*	55% of energy from CHO, <30% fat, limited energy intake	58/68	ITT analysis
Frisch <i>et al</i> (2009) ⁸⁷ ** Germany	100/100	47 Both	33.5	12	<40% energy from CHO, >35% from fat**	>55% CHO, < 35% energy from fat	95/89	ITT analysis
Gardner <i>et</i> al (2007) ⁸⁸ * USA	77/76	41.3 F	32	12	Atkins 20g/d CHO, after 3 months gradual increase of CHO of 5g/d*	Ornish diet (70% CHO, 10% energy from fat)	88/78	ITT analysis
Klemsdal <i>et al</i> (2010) ⁸⁹ ** Norway	100/102	46.8 Both	35.4	12	35-40% energy from fat, 35% from CHO**	<30% energy from fat, 55- 60% from CHO	78/84	ITT analysis
Morgan <i>et</i> al (2009) ⁹⁰ * UK	57/58	40.7 Both	31.6	6	Atkins New Diet Revolution 20g/d CHO, after 3 month <50 g/d CHO**	Eat Yourself Slim – controlled low fat healthy diet + fitness	72	ITT analysis
Sacks <i>et al</i> (2009) ⁹¹ ** USA	204/204	51.5 Both	33	24	40% energy from fat, 40% from CHO**	65% CHO and 20% fat, average protein	82/83	ITT analysis

Table 3. Characteristics of included trials

*very low carbohydrate diet intervention; ** moderate low carbohydrate diet intervention

BMI, body mass index; CRD, carbohydrate restricted diet; LFD, low fat diet; CHO, carbohydrate; MUFA, monounsaturated fatty acids; ITT, Intention-to-treat

 Table 4. Baseline lipid variables (mmol/L) among study participants by dietary intervention

Intervention		CRD				LFI)	
Parameter	LDL-C	HDL-C	TG	TC	LDL-C	HDL-C	TG	TC
mmol/L	(SD)							
Bazzano	3.20	1.40	1.30	5.1	3.30	1.22	1.40	5.3
<i>et al</i> (2014) ⁸⁴	(0.9)	(0.32)	(0.6)	(1.1)	(1.0)	(0.3)	(0.9)	(1.1)
Due et al	2.75	1.22	1.02	4.44	2.78	1.23	1.15	4.52
$(2008)^{85}$	(0.8)	(0.6)	(0.37)	(0.74)	(0.9)	(0.42)	(0.8)	(1.04)
Foster et al	3.11	1.20	1.28	4.88	3.21	1.18	1.40	4.98
$(2010)^{86}$	(0.67)	(0.35)	(0.62)	(0.78)	(0.76)	(0.30)	(0.83)	(0.85)
Frisch et al	3.54	1.49	1.31	5.50	3.56	1.46	1.59	5.54
$(2009)^{87}$	(0.8)	(0.37)	(0.56)	(0.93)	(0.91)	(0.37)	(0.65)	(1.10)
Gardner	2.82	1.37	1.41	na	2.87	1.29	1.3	na
$et \ al \ (2007)^{88}$	(0.75)	(0.36)	(0.88)		(0.70)	(0.28)	(0.7)	
Klemsdal	3.76	1.28	1.93	5.8	3.84	1.29	1.91	6.0
$et \ al \ (2010)^{89}$	(0.94)	(0.37)	(1.21)	(0.97)	(1.01)	(0.37)	(1.13)	(1.04)
Morgan	3.72	1.22	1.65	na	3.59	1.22	1.59	na
<i>et al</i> $(2009)^{90}$	(0.52)	(0.23)	(0.7)		(0.67)	(0.3)	(0.83)	
Sacks et al	3.21	1.27	1.52	5.26	3.31	1.24	1.66	5.15
$(2009)^{91}$	(0.85)	(0.39)	(0.92)	(0.96)	(0.83)	(0.1)	(1.05)	(0.98)

CRD, carbohydrate restricted diet; LFD, low fat diet; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol, TG, triglycerides; TC, total cholesterol; SD, standard deviation.

Figure 1. Flow diagram of literature search

Figure 2. Quality assessment of each included study (n = 8) using the Cochrane Risk of Bias Tool

Figure 3. Risk of bias (%) across included studies (n = 8) using the Cochrane Risk of Bias Tool: selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias.

Figure 4. Forest plot for LDL-C changes between CRD and LFD at 6, 12, and 24 months compared to baseline (mmol/L). *Abbreviations:* CRD, carbohydrate restricted diet; LFD, low fat diet; LDL, low density lipoprotein.

Figure 5. Forest plot for LDL-C changes between VLCD and LFD at 6, 12 and 24 months compared to baseline (mmol/L). *Abbreviations*: VLCD, very low carbohydrate diet; LFD, low fat diet; LDL, low density lipoprotein.

Figure 6. Forest plot for LDL-C changes between MLCD and LFD at 6, 12 and 24 months compared to baseline (mmol/L). *Abbreviations*: MLCD, moderate low carbohydrate diet; LFD, low fat diet; LDL, low density lipoprotein.

Figure 7. Forest plot for HDL-C changes between CRD and LFD at 6, 12 and 24 months compared to baseline (mmol/L). *Abbreviations*: CRD, carbohydrate restricted diet; LFD, low fat diet; HDL, high density lipoprotein.

Figure 8. Forest plot for TG changes between CRD and LFD at 6, 12 and 24 months compared to baseline (mmol/L). *Abbreviations*: CRD, carbohydrate restricted diet; LFD, low fat diet; HDL, high density lipoprotein.


Figure 9. Forest plot for HDL-C changes between VLCD and LFD at 6, 12 and 24 months compared to baseline (mmol/L). *Abbreviations*: VLCD, very low carbohydrate diet; LFD, low fat diet; HDL, high density lipoprotein.


Figure 10. Forest plot for TG changes between VLCD and LFD at 6, 12 and 24 months compared to baseline (mmol/L). *Abbreviations*: VLCD, very low carbohydrate diet; LFD, low fat diet; TG, triglycerides.

Figure 11. Forest plot for HDL-C changes between MLCD and LFD at 6, 12 and 24 months compared to baseline (mmol/L). *Abbreviations*: MLCD, moderate low carbohydrate diet; LFD, low fat diet; HDL, high density lipoprotein.

Figure 12. Forest plot for TG changes between MLCD and LFD at 6, 12 and 24 months compared to baseline (mmol/L). *Abbreviations*: MLCD, moderate low carbohydrate diet; LFD, low fat diet; TG, triglycerides.

Figure 13. Forest plot for Total Cholesterol changes between CRD and LFD at 6, 12 and 24 months compared to baseline (mmol/L). *Abbreviations*: CRD, carbohydrate restricted diet; LFD, low fat diet.





190x166mm (96 x 96 DPI)




Figure 2. Quality assessment of each included study (n = 8) using the Cochrane Risk of Bias Tool




Figure 3. Risk of bias (%) across included studies (n = 8) using the Cochrane Risk of Bias Tool: selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias.

176x102mm (87 x 63 DPI)

		CRD	22000		LFD			Mean Difference	Mean Difference
Study or Subgroup	Mean		Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.1.1 LDL-C change a	t 6 mont	hs							
Bazzano 2014 (84)	-0.04	0.4781	75	0.02	0.4286	73	8.2%	-0.06 [-0.21, 0.09]	
Due 2008 (85)	-0.08	0.431	52	0.01	0.6543	48	4.9%	-0.09 [-0.31, 0.13]	
Foster 2010 (86)	0.014	0.5885	153	-0.24	0.5653	154	9.4%	0.25 [0.12, 0.38]	
Frisch 2009 (87)	-0.03	0.5	100	-0.03	0.51	100	8.6%	0.00 [-0.14, 0.14]	
Gardner 2007 (88)	0.04	0.58	77	-0.08	0.5	76	6.8%	0.12 [-0.05, 0.29]	
Klemsdal 2010 (89)	-0.01	0.89	100	-0.12	0.92	102	4.0%	0.11 [-0.14, 0.36]	
Morgan 2009 (90)	-0.16	0.76	57	-0.44	0.57	58	4.1%	0.28 [0.03, 0.53]	
Sacks 2009 (91)	-0.13	0.85	204	-0.21	0.75	204	7.7%	0.08 [-0.08, 0.24]	
Subtotal (95% CI)			818			815	53.7%	0.08 [-0.01, 0.18]	◆
Heterogeneity: Tau ² =	0.01; Ch	² = 16.85	, df = 7	(P = 0.0)	2); I ² = 58	3%			
Test for overall effect:	Z=1.72	(P = 0.08)							
1.1.2 LDL-C change a	fter 12 m	nonths							
Bazzano 2014 (84)	-0.08	0.6954	75	-0.05	0.6429	73	5.0%	-0.03 [-0.25, 0.19]	
Foster 2010 (86)	-0.222	0.6762	153	-0.224	0.6658	154	8.0%	0.00 [-0.15, 0.15]	
Frisch 2009 (87)	0.02	0.65	100	0.06	0.59	100	6.8%	-0.04 [-0.21, 0.13]	
Gardner 2007 (88)	0.02	0.58	77	-0.1	0.49	76	6.9%	0.12 [-0.05, 0.29]	
Klemsdal 2010 (89)	0.06	0.83	100	-0.14	0.92	102	4.2%	0.20 [-0.04, 0.44]	
Subtotal (95% CI)			505			505	30.8%	0.04 [-0.04, 0.12]	+
Heterogeneity: Tau ² =	0.00; Ch	² = 4.01,	df = 4 (l	P = 0.40); I ² = 0%				
Test for overall effect:	Z = 0.90	(P = 0.37)							
1.1.3 LDL-C change a	fter 24 m	nonths							
Foster 2010 (86)	-0.12	0.7519	153	-0.2	0.5653	154	8.1%	0.08 [-0.07, 0.23]	
Sacks 2009 (91)	-0.05	0.85	204	-0.18	0.8	204	7.4%	0.13 [-0.03, 0.29]	
Subtotal (95% CI)			357			358	15.5%	0.10 [-0.01, 0.21]	◆
Heterogeneity: Tau ² =	0.00; Ch	² = 0.20,	df = 1 (l	P = 0.65); I ² = 0%				
Test for overall effect:	Z = 1.85	(P = 0.06)							
Total (95% CI)			1680			1678	100.0%	0.07 [0.02, 0.13]	•
Heterogeneity: Tau ² =	0.00 [.] Ch	² = 22.25	df = 1	4 (P = 0)	$(07) \cdot 1^2 = 3$				
Test for overall effect:									-0.5 -0.25 0 0.25 0.5
Test for subgroup diff									Favours CRD Favours LFD

Figure 4. Forest plot for LDL-C changes between CRD and LFD at 6, 12, and 24 months compared to baseline (mmol/L). Abbreviations: CRD, carbohydrate restricted diet; LFD, low fat diet; LDL, low density lipoprotein.

		VLCD			LFD			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.4.1 LDL-C change	/LCD vs	LFD at 6	months	6					10 I I I I I I I I I I I I I I I I I I I
Bazzano 2014 (84)	-0.04	0.4781	75	0.02	0.4286	73	13.5%	-0.06 [-0.21, 0.09]	
Foster 2010 (86)	0.014	0.5885	153	-0.24	0.5653	154	14.2%	0.25 [0.12, 0.38]	
Gardner 2007 (88)	0.04	0.58	77	-0.08	0.5	76	12.5%	0.12 [-0.05, 0.29]	
Morgan 2009 (90)	-0.16	0.76	57	-0.44	0.57	58	9.7%	0.28 [0.03, 0.53]	
Subtotal (95% CI)			362			361	49.9%	0.14 [-0.02, 0.30]	◆
Heterogeneity: Tau ² =	0.02; Ch	i ² = 11.4	6, df = 3	B(P = 0.00))9); I ² = 7	4%			
Test for overall effect:	Z=1.69	(P = 0.09))						
1.4.2 LDL-C change	/LCD vs	LFD at 12	month	15					
Bazzano 2014 (84)	-0.08	0.6954	75	-0.05	0.6429	73	10.8%	-0.03 [-0.25, 0.19]	
Foster 2010 (86)	-0.222	0.6762	153	-0.0224	0.6658	154	13.4%	-0.20 [-0.35, -0.05]	
Gardner 2007 (88)	0.02	0.58	77	-0.1	0.49	76	12.6%	0.12 [-0.05, 0.29]	
Subtotal (95% CI)			305			303	36.7%	-0.04 [-0.24, 0.16]	-
Heterogeneity: Tau ² =	0.02; Ch	i ² = 7.68,	df = 2	(P = 0.02)	; I ² = 74%	5			
Test for overall effect:	Z = 0.39	(P = 0.70))						
1.4.3 LDL-C change	/LCD vs	LFD at 24	month	15					
Foster 2010 (86)	-0.12	0.7519	153	-0.2	0.5653	154	13.4%	0.08 [-0.07, 0.23]	-+
Subtotal (95% CI)			153			154	13.4%	0.08 [-0.07, 0.23]	-
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z=1.05	(P = 0.29	0						
Total (95% CI)			820			818	100.0%	0.07 [-0.05, 0.18]	•
Heterogeneity: Tau ² =	0.02; Ch	i ² = 27.4	9, df = 7	P = 0.00	003); I ² =	75%		100	
Test for overall effect:				10					-0.5 -0.25 0 0.25 0.5
Test for subaroup diff		•		= 2 (P = 0	39), I ² = 0	1%			Favours VLCD Favours LFD

Figure 5. Forest plot for LDL-C changes between VLCD and LFD at 6, 12 and 24 months compared to baseline (mmol/L). Abbreviations: VLCD, very low carbohydrate diet; LFD, low fat diet; LDL, low density lipoprotein.

	1	ALCD			LFD			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.5.1 LDL-C change N	ILCD vs I	FD at 6	month	15					
Due 2008 (85)	-0.08	0.431	52	0.01	0.6543	48	9.5%	-0.09 [-0.31, 0.13]	
Frisch 2009 (87)	-0.03	0.5	100	-0.03	0.51	100	23.3%	0.00 [-0.14, 0.14]	-+-
Klemsdal 2010 (89)	-0.01	0.89	100	-0.12	0.92	102	7.3%	0.11 [-0.14, 0.36]	
Sacks 2009 (91)	-0.13	0.85	204	-0.21	0.75	204	18.9%	0.08 [-0.08, 0.24]	-+
Subtotal (95% CI)			456			454	59.0%	0.02 [-0.06, 0.11]	*
Heterogeneity: Tau ² =	0.00; Ch	² = 2.11	, df = 3	(P = 0.	55); I ² = (9%			
Test for overall effect:	Z = 0.55	(P = 0.5	8)						
1.5.2 LDL-C change N	ILCD vs I	FD at 1	2 mon	ths					
Frisch 2009 (87)	0.02	0.65	100	0.06	0.59	100	15.4%	-0.04 [-0.21, 0.13]	
Klemsdal 2010 (89)	0.06	0.83	100	-0.14	0.92	102	7.8%	0.20 [-0.04, 0.44]	+
Subtotal (95% CI)			200			202	23.2%	0.06 [-0.17, 0.30]	
Heterogeneity: Tau ² =	0.02; Ch	² = 2.52	, df = 1	(P = 0.	11); 2 = 6	60%			
Test for overall effect:	Z=0.54	(P = 0.5	9)						
1.5.3 LDL-C change N	ILCD vs I	FD at 2	4 mon	ths					
Sacks 2009 (91)	-0.05	0.85	204	-0.18	0.8	204	17.8%	0.13 [-0.03, 0.29]	
Subtotal (95% CI)			204			204	17.8%	0.13 [-0.03, 0.29]	
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z=1.59	(P = 0.1	1)						
Total (95% CI)			860			860	100.0%	0.05 [-0.02, 0.11]	•
Heterogeneity: Tau ² =	0.00; Ch	² = 5.91	. df = 6	(P = 0)	43); I ² = (0%			- Ja da l'ala da
Test for overall effect:									-0.5 -0.25 0 0.25 0.5
Test for subaroup diff		•		- 2 /0 -	0.500 13	- 00/			Favours MLCD Favours LFD

Figure 6. Forest plot for LDL-C changes between MLCD and LFD at 6, 12 and 24 months compared to baseline (mmol/L). Abbreviations: MLCD, moderate low carbohydrate diet; LFD, low fat diet; LDL, low density lipoprotein.

		CRD			LFD			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.2.1 HDL-C change a	t 6 mon	ths							
Bazzano 2014 (84)	0.1	0.1884	75	0	0.1902	73	7.8%	0.10 [0.04, 0.16]	
Due 2008 (85)	0.09	0.32	52	0.05	0.17	48	4.7%	0.04 [-0.06, 0.14]	
Foster 2010 (86)	0.16	0.2504	153	0.02	0.1633	154	9.3%	0.14 [0.09, 0.19]	
Frisch 2009 (87)	-0.02	0.2	100	-0.09	0.19	100	8.5%	0.07 [0.02, 0.12]	
Gardner 2007 (88)	0.13	0.25	77	0	0.24	76	6.2%	0.13 [0.05, 0.21]	
Klemsdal 2010 (89)	0.08	0.35	100	0.08	0.39	102	4.5%	0.00 [-0.10, 0.10]	
Morgan 2009 (90)	-0.08	0.32	57	-0.2	0.25	58	4.3%	0.12 [0.01, 0.23]	
Sacks 2009 (91)	0.07	0.33	204	-0.01	0.39	204	6.9%	0.08 [0.01, 0.15]	
Subtotal (95% CI)			818			815	52.1%	0.09 [0.06, 0.12]	•
Heterogeneity: Tau ² =	0.00; Ch	i ² = 9.97,	df = 7	(P = 0.1)	9); I ² = 30	0%			
Test for overall effect:	Z = 6.10	(P < 0.00	1001)						
1.2.2 HDL-C change a	at 12 mo	nths							
Bazzano 2014 (84)	0.24	0.2638	75	0.06	0.2662	73	5.6%	0.18 [0.09, 0.27]	
oster 2010 (86)	0.21	0.313	153	0.1	0.2513	154	7.5%	0.11 [0.05, 0.17]	
Frisch 2009 (87)	-0.02	0.21	100	-0.03	0.17	100	8.6%	0.01 [-0.04, 0.06]	
Gardner 2007 (88)	0.127	0.23	77	0	0.16	76	7.6%	0.13 [0.06, 0.19]	
Klemsdal 2010 (89)	0.12	0.35	100	0.11	0.44	102	4.1%	0.01 [-0.10, 0.12]	
Subtotal (95% CI)			505			505	33.5%	0.09 [0.02, 0.15]	◆
Heterogeneity: Tau ² =	0.00; Ch	i ² = 16.5	4, df = 4	(P = 0.	.002); I ² =	76%			
Test for overall effect:	Z = 2.68	(P = 0.00	17)						
1.2.3 HDL-C change a	t 24 mo	nths							
oster 2010 (86)	0.2	0.313	153	0.12	0.2513	154	7.5%	0.08 [0.02, 0.14]	
Sacks 2009 (91)	0.163	0.33	204	0.14	0.39	204	6.9%	0.02 [-0.05, 0.09]	
Subtotal (95% CI)			357			358	14.4%	0.05 [-0.00, 0.11]	◆
Heterogeneity: Tau ² =	0.00; Ch	i ² = 1.39,	df = 1	(P = 0.2)	4); I ² = 28	3%			
Fest for overall effect:	Z=1.88	(P = 0.08	i)						
Total (95% CI)			1680			1678	100.0%	0.08 [0.06, 0.11]	•
Heterogeneity: Tau ² =	0.00; Ch	i ² = 30.4	9, df = 1	4 (P = 1	0.007); I ²	= 54%			
Fest for overall effect:									-0.5 -0.25 0 0.25 0.5
Fest for subaroup diff				- 2 /P -	0.46) 12-	- 0.96			Favours CRD Favours LCD

Figure 7. Forest plot for HDL-C changes between CRD and LFD at 6, 12 and 24 months compared to baseline (mmol/L). Abbreviations: CRD, carbohydrate restricted diet; LFD, low fat diet; HDL, high density lipoprotein.

		CRD			LFD			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.3.1 TG change at 6	months								
Bazzano 2014 (84)	-0.22	0.3392	75	-0.01	0.3423	73	10.2%	-0.21 [-0.32, -0.10]	
Due 2008 (85)	-0.15	0.5388	52	-0.15	0.5166	48	5.0%	0.00 [-0.21, 0.21]	
Foster 2010 (86)	-0.45	0.3756	153	-0.27	0.5025	154	11.0%	-0.18 [-0.28, -0.08]	
Frisch 2009 (87)	-0.18	0.4	100	-0.03	0.55	100	8.6%	-0.15 [-0.28, -0.02]	
Gardner 2007 (88)	-0.4	0.73	77	-0.085	0.6	76	4.8%	-0.32 [-0.53, -0.10]	
Klemsdal 2010 (89)	-0.37	0.93	100	-0.34	0.71	102	4.3%	-0.03 [-0.26, 0.20]	
Morgan 2009 (90)	-0.64	0.33	57	-0.28	0.52	58	7.0%	-0.36 [-0.52, -0.20]	
Sacks 2009 (91)	-0.2	0.99	204	-0.13	0.94	204	5.7%	-0.07 [-0.26, 0.12]	
Subtotal (95% CI)			818			815	56.7%	-0.18 [-0.25, -0.10]	•
Heterogeneity: Tau ² =	0.00; Ch	ni² = 12.80	6, df = 7	P = 0.0	08); I ² = 4	6%			
Test for overall effect:	Z = 4.65	(P < 0.00	1001)						
1.3.2 TG change at 12	2 months	5							
Bazzano 2014 (84)	-0.23	0.4781	75	-0.07	0.6429	73	5.9%	-0.16 [-0.34, 0.02]	
Foster 2010 (86)	-0.35	0.5635	153	-0.2	0.7538	154	7.6%	-0.15 [-0.30, -0.00]	
Frisch 2009 (87)	-0.1	0.47	100	-0.04	0.5	100	8.5%	-0.06 [-0.19, 0.07]	
Gardner 2007 (88)	-0.33	0.66	77	-0.17	0.52	76	5.7%	-0.16 [-0.35, 0.03]	
Klemsdal 2010 (89)	-0.26	1.03	100	-0.29	0.81	102	3.6%	0.03 [-0.23, 0.29]	
Subtotal (95% CI)			505			505	31.3%	-0.11 [-0.18, -0.03]	•
Heterogeneity: Tau ² =	0.00; Ch	ni ² = 2.52,	df = 4	(P = 0.64)	4); I ² = 0%				
Test for overall effect:	Z = 2.81	(P = 0.00	15)						
1.3.3 TG change at 24	4 months	5							
Foster 2010 (86)	-0.14	0.7513	153	-0.16	0.8166	154	6.2%	0.02 [-0.16, 0.20]	
Sacks 2009 (91)	-0.14	0.98	204	-0.13	0.94	204	5.8%	-0.01 [-0.20, 0.18]	<u> </u>
Subtotal (95% CI)			357			358	12.0%	0.01 [-0.12, 0.13]	•
Heterogeneity: Tau ² =	0.00; Ch	ni² = 0.05,	df = 1	(P = 0.82	2); I ² = 0%				
Test for overall effect:	Z = 0.09	(P = 0.93)						
Total (95% CI)			1680			1678	100.0%	-0.13 [-0.19, -0.08]	•
Heterogeneity: Tau ² =	0.00; Cł	ni² = 23.60	D, df = 1	4(P = 0	.05); I ² =	41%		-	
Test for overall effect:				2					-0.5 -0.25 0 0.25 0.5
Test for subgroup diff				2 (P = 0	1.05) I ² =	66.7%			Favours CRD Favours LFD

Figure 8. Forest plot for TG changes between CRD and LFD at 6, 12 and 24 months compared to baseline (mmol/L). Abbreviations: CRD, carbohydrate restricted diet; LFD, low fat diet; HDL, high density lipoprotein.




Figure 9. Forest plot for HDL-C changes between VLCD and LFD at 6, 12 and 24 months compared to baseline (mmol/L). Abbreviations: VLCD, very low carbohydrate diet; LFD, low fat diet; HDL, high density lipoprotein.

Study or Subgroup	Mean	VLCD	Total	Mean	LFD	Total	Moight	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% CI
3.4.1 TG change VLC				weall	30	TOLAI	weight	IV, Ralluolli, 95% Ci	IV, Kalluolli, 95% CI
-					10020001		101011	200000000000000000000000000000000000000	
Bazzano 2014 (84)		0.3392	75		0.3423	73		-0.21 [-0.32, -0.10]	
Foster 2010 (86)		0.3756	153		0.5025	154		-0.18 [-0.28, -0.08]	
Gardner 2007 (88)	-0.4	0.73	77	-0.085	0.6	76	8.1%	-0.32 [-0.53, -0.10]	
Morgan 2009 (90)	-0.64	0.33	57	-0.28	0.52	58	12.0%	-0.36 [-0.52, -0.20]	
Subtotal (95% CI)			362			361	57.0%	-0.24 [-0.32, -0.16]	•
Heterogeneity: Tau ² =	0.00; C	hi ² = 4.29	, df = 3	(P = 0.2)	3); I ² = 30	9%			
Test for overall effect:	Z = 5.92	(P < 0.0	0001)						
3.4.2 TG change VLC	D vs LFC) at 12 m	onths						
Bazzano 2014 (84)	-0.23	0.4781	75	-0.07	0.6429	73	9.9%	-0.16 [-0.34, 0.02]	
Foster 2010 (86)	-0.35	0.5635	153	-0.2	0.7538	154	12.9%	-0.15 [-0.30, -0.00]	
Gardner 2007 (88)	-0.33	0.66	77	-0.17	0.52	76	9.6%	-0.16 [-0.35, 0.03]	
Subtotal (95% CI)			305			303	32.5%	-0.16 [-0.25, -0.06]	•
Heterogeneity: Tau ² =	0.00; C	hi ² = 0.01	. df = 2	(P = 1.0	0); $I^2 = 09$	16			
Test for overall effect:	Z = 3.10	(P = 0.0	02)						
3.4.3 TG change VLC	D vs LFC) at 24 m	onths						
Foster 2010 (86)	-0.14	0.7513	153	-0.16	0.8166	154	10.5%	0.02 [-0.16, 0.20]	
Subtotal (95% CI)			153			154	10.5%	0.02 [-0.16, 0.20]	•
Heterogeneity: Not ap	plicable								
Test for overall effect:			2)						
			·						
Total (95% CI)			820			818	100.0%	-0.19 [-0.26, -0.12]	•
Heterogeneity: Tau ² =	0.00; C	hi ² = 11.8	8. df =	7 (P = 0.	$10); I^2 = 4$	1%			to the house
Test for overall effect:									-0.5 -0.25 0 0.25 0.5
Test for subaroup diff									Favours VLCD Favours LFD

Figure 10. Forest plot for TG changes between VLCD and LFD at 6, 12 and 24 months compared to baseline (mmol/L). Abbreviations: VLCD, very low carbohydrate diet; LFD, low fat diet; TG, triglycerides.




Figure 11. Forest plot for HDL-C changes between MLCD and LFD at 6, 12 and 24 months compared to baseline (mmol/L). Abbreviations: MLCD, moderate low carbohydrate diet; LFD, low fat diet; HDL, high density lipoprotein.

		MLCD			LFD			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
3.5.1 TG change MLC	D vs LFD	at 6 mor	nths						
Due 2008 (85)	-0.15	0.5388	52	-0.15	0.5166	48	10.3%	0.00 [-0.21, 0.21]	
Frisch 2009 (87)	-0.18	0.4	100	-0.03	0.55	100	24.8%	-0.15 [-0.28, -0.02]	
Klemsdal 2010 (89)	-0.37	0.93	100	-0.34	0.71	102	8.5%	-0.03 [-0.26, 0.20]	
Sacks 2009 (91) Subtotal (95% CI)	-0.2	0.99	204 456	-0.13	0.94	204 454	12.6% 56.2%	-0.07 [-0.26, 0.12] -0.09 [-0.18, 0.00]	•
Heterogeneity: Tau ² =	0.00; Ch	i ² = 1.81,	df = 3	(P = 0.6)	1); $I^2 = 09$	6			
Test for overall effect: .	Z = 1.91	(P = 0.06)						
3.5.2 TG change MLC	D vs LFD	at 12 m	onths						
Frisch 2009 (87)	-0.1	0.47	100	-0.04	0.5	100	24.4%	-0.06 [-0.19, 0.07]	
Klemsdal 2010 (89) Subtotal (95% CI)	-0.26	1.03	100 200	-0.29	0.81	102 202	6.7% 31.1%	0.03 [-0.23, 0.29] -0.04 [-0.16, 0.08]	•
Heterogeneity: Tau ² =	0.00; Ch	i ² = 0.37,	df = 1	(P = 0.5)	4); I ² = 09	6			
Test for overall effect: .	Z = 0.67	(P = 0.50)						
3.5.3 TG change MLC	D vs LFD	at 24 m	onths						
Sacks 2009 (91) Subtotal (95% CI)	-0.14	0.98	204 204	-0.13	0.94	204 204	12.7% 12.7%	-0.01 [-0.20, 0.18] -0.01 [-0.20, 0.18]	-
Heterogeneity: Not ap Test for overall effect: .		(P = 0.92)						
Total (95% CI)			860			860	100.0%	-0.06 [-0.13, 0.00]	•
Heterogeneity: Tau ² =	0.00; Ch	i ² = 2.90,	df = 6	(P = 0.8	2); I ² = 09	6			-0.5 -0.25 0 0.25 0.5
Test for overall effect: .	Z=1.84	(P = 0.07)		1.12				-0.5 -0.25 0 0.25 0.5 Favours MLCD Favours LFD

Figure 12. Forest plot for TG changes between MLCD and LFD at 6, 12 and 24 months compared to baseline (mmol/L). Abbreviations: MLCD, moderate low carbohydrate diet; LFD, low fat diet; TG, triglycerides.




Figure 13. Forest plot for Total Cholesterol changes between CRD and LFD at 6, 12 and 24 months compared to baseline (mmol/L). Abbreviations: CRD, carbohydrate restricted diet; LFD, low fat diet.



Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	1-2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	2-4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	Not registered
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5-6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	4-5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Supplementary material
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5-6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6-7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	5-6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6-7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	7-8



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6-7
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	7
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8 (Figure 1)
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8-9
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	10
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	10-14
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10-14
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	13-14
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	10-14
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14-20
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	20-21
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	21-22
FUNDING	•		
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	22

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Search strategy

Medline and CINAHL (EBSCO)

- #1 Diet, Carbohydrate-Restricted. mm
- #2 (low carbohydrate). ti, kw.
- #3 (carbohydrate N2 restrict*).ti, kw.
- #4 Ketogenic Diet. mm
- #5 (ketogenic and diet*).ti, kw.
- #6 (atkins and diet*).ti, kw.
- #7 1 or 2 or 3 or 4 or 5 or 6
- #8 Diet, Fat-Restricted. mm
- #9 (fat N2 restrict*).ti, kw.
- #10 low fat. ti, kw.
- #11 (conventional and diet*). ti, kw.
- #12 8 or 9 or 10 or 11
- #13 7 and 12
- #14 Dyslipidemias. mm
- #15 Lipoproteins. mm
- #16 (low density lipoprotein). ti, ab
- #17 (cholesterol). ti, ab
- #18 (LDL*). ti, ab
- #19 (lipid profil*). kw, ab
- # 20 (Dyslipid*). kw, ab
- # 21 (high density lipoprotein). ti, ab
- # 22 (HDL*). ti, ab
- # 23 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
- #24 13 and 23
- # 25 (Random* controlled trial). Pt
- # 26 (Controlled clinical trial). Pt
- #27 Random*. ab
- # 28 Trial*. ab
- #29 Placebo*. ab
- # 30 Group*. ab
- # 31 25 or 26 or 27 or 28 or 29 or 30
- # 32 Animals. mm not humans. mw
- # 33 31 not 32
- # 34 24 and 33

Pubmed central

- #1 Diet, Carbohydrate-Restricted. mh
- #2 low carbohydrate. ti, kw.
- #3 "carbohydrate N2 restrict*".ti, kywd.
- #4 Ketogenic Diet. mh
- #5 "ketogenic and diet*".ti, kywd.
- #6 "atkins and diet*".ti, kywd.
- #7 1 or 2 or 3 or 4 or 5 or 6
- #8 Diet, Fat-Restricted. mh

- #9 "fat N2 restrict*".ti, kywd.
- #10 low fat. ti, kywd.
- #11 "conventional and diet*". ti, kywd.
- #12 8 or 9 or 10 or 11
- #13 7 and 12
- #14 Dyslipidemias. mh
- #15 Lipoproteins. mh
- #16 "low density lipoprotein". ti, ab
- #17 "cholesterol". ti, ab
- #18 "LDL*". ti, ab
- #19 "lipid profil*". kywd, ab
- # 20 "Dyslipid*". kywd, ab
- # 21 "high density lipoprotein". ti, ab
- # 22 "HDL*". ti, ab
- # 23 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
- #24 13 and 23
- # 25 "Random* controlled trial". Pt
- #26 "Controlled clinical trial". Pt
- # 27 Random*. ab
- # 28 Trial*. ab
- # 29 Placebo*. ab
- # 30 Group*. ab
- # 31 25 or 26 or 27 or 28 or 29 or 30
- # 32 Animals. mh not humans. mh
- # 33 31 not 32
- # 34 24 and 33

Cochrane Library Trials

- #1 MeSH descriptor: [Diet, Carbohydrate-Restricted]
- #2 "low carbohydrate". ti, ab, kw.
- #3 carbohydrate near/2 restrict*.ti, ab, kw.
- #4 MeSH descriptor: [Ketogenic Diet]
- #5 (ketogenic and diet*).ti, ab, kw.
- #6 (atkins and diet*).ti, ab, kw.
- #7 1 or 2 or 3 or 4 or 5 or 6
- #8 MeSH descriptor: [Diet, Fat-Restricted]
- #9 (fat near/2 restrict*).ti, ab, kw.
- #10 "low fat". ti, ab, kw.
- #11 "conventional and diet*". ti, ab, kw.
- #12 8 or 9 or 10 or 11
- #13 7 and 12
- #14 MeSH descriptor: [Dyslipidemias]
- #15 MeSH descriptor: [Lipoproteins]
- #16 "low density lipoprotein". ti, ab, kw
- #17 "cholesterol". ti, ab, kw
- #18 "LDL*". ti, ab, kw
- # 19 "lipid profil*". kw, ab

- # 20 "Dyslipid*". kw, ab
- # 21 "high density lipoprotein". ti, ab, kw
- # 22 "HDL*". ti, ab, kw
- # 23 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
- #24 13 and 23
- # 25 MeSH descriptor [Randomized controlled trial]
- #26 MeSH descriptor [Controlled clinical trial]
- # 27 25 or 26
- # 28 MeSH descriptor [Animals] not MeSH descriptor [humans]
- # 29 27 not 28
- # 30 24 and 29

Outcome or Subgroup	Studies	Participants	Mean Difference	Р	I ²
(mmol/L)			(Random, 95% CI)		
Mean LDL-C change	8	3358	0.07 [0.02, 0.13]	0.009	36
LDL- C change at 6 months	8	1633	0.08 [-0.01, 0.18]	0.08	58
LDL-C change after 12 months	5	1010	0.04 [-0.04, 0.12]	0.37	1
LDL-C change after 24 months	2	715	0.10 [-0.01, 0.21]	0.06	0
Mean HDL-C change	8	3358	0.08 [0.06, 0.11]	1x10 ⁻⁵	52
HDL-C change at 6 months	8	1633	0.09 [0.06, 0.12]	1×10^{-5}	28
HDL-C change at 12 months	5	1010	0.09 [0.02, 0.15]	0.004	74
HDL-C change at 24 months	2	715	0.05 [-0.00, 0.11]	0.06	28
Mean TG change	8	3358	-0.13 [-0.19, -0.08]	1x10 ⁻⁵	40
TG change at 6 months	8	1633	-0.18 [-0.25, -0.10]	1×10^{-5}	43
TG change at 12 months	5	1010	-0.11 [-0.18, -0.03]	0.005	0
TG change at 24 months	2	715	0.01 [-0.12, 0.13]	0.93	0
Mean TC change	6	2937	0.00 [-0.01, -0.00]	0.002	0
TC change at 6 months	6	1365	-0.01 [-0.01, -0.00]	0.02	0
TC change at 12 months	4	857	-0.01 [-0.04, 0.03]	0.78	6
TC change at 24 months	2	715	-0.00 [-0.01, 0.00]	0.66	0

Table S1. Weighted mean difference of LDL-C, HDL-C, TG, and TC between CRD and LFD at 6, 12 and 24 months compared to baseline (mmol/L)

LDL-C, low density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; TG, plasma triglycerides; TC, total cholesterol; CRD, carbohydrate restricted diet; LFD-low fat diet

Table S2. Weighted mean difference of LDL-C, HDL-C and TG between VLCD and LFD at 6, 12 and 24 months compared to baseline (mmol/L)

Outcome or Subgroup	Studies	Participants	Mean Difference	Р	\mathbf{I}^2
(mmol/L)			(Random, 95% CI)		%
Mean LDL-C change	4	1638	0.07 [-0.05, 0.18]	0.27	75
LDL- C change at 6 months	4	723	0.14 [-0.02, 0.30]	0.09	74
LDL-C change after 12 months	3	608	-0.04 [-0.24, 0.16]	0.70	74
LDL-C change after 24 months	1	307	0.08 [-0.07, 0.23]	0.29	N/A
Mean HDL-C change	4	1638	0.12 [0.10, 0.14]	1×10^{-5}	0
HDL-C change at 6 months	4	723	0.13 [0.09, 0.16]	1×10^{-5}	0
HDL-C change at 12 months	3	608	0.13 [0.09, 0.17]	1×10^{-5}	0
HDL-C change at 24 months	1	307	0.08 [0.02, 0.14]	0.01	N/A
Mean TG change	4	1638	-0.19 [-0.26, -0.12]	1×10^{-5}	41
TG change at 6 months	4	723	-0.24 [-0.32, -0.16]	1×10^{-5}	30
TG change at 12 months	3	608	-0.16 [-0.25, -0.06]	0.002	0
TG change at 24 months	1	307	0.02 [-0.16, 0.20]	0.82	N/A

LDL-C, low density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; TG, plasma triglycerides; N/A, not applicable; VLCD, very low carbohydrate diet; LFD, low fat diet

Outcome or Subgroup	Studies	Participants	Mean Difference	Р	I^2
(mmol/L)		-	(Random, 95% CI)		%
Mean LDL-C change	4	1720	0.05 [-0.02, 0.11]	0.16	0
LDL- C change at 6 months	4	910	0.02 [-0.06, 0.11]	0.54	0
LDL-C change after 12 months	2	402	0.06 [-0.17, 0.30]	0.59	60
LDL-C change after 24 months	1	408	0.13 [-0.03, 0.29]	0.11	N/A
Mean HDL-C change	4	1720	0.04 [0.01, 0.07]	0.005	0
HDL-C change at 6 months	4	910	0.06 [0.02, 0.10]	0.02	0
HDL-C change at 12 months	2	402	0.01 [-0.04, 0.06]	0.68	0
HDL-C change at 24 months	1	408	0.02 [-0.05, 0.09]	0.52	N/A
Mean TG change	4	1720	-0.06 [-0.13, 0.00]	0.06	0
TG change at 6 months	4	910	-0.09 [-0.18, 0.00]	0.05	0
TG change at 12 months	2	402	-0.04 [-0.16, 0.08]	0.5	0
TG change at 24 months	1	408	-0.01 [-0.20, 0.18]	0.92	N/A

Table S3. Weighted mean difference of LDL-C, HDL-C and TG between MLCD and LFD at 6, 12 and 24 months compared to baseline (mmol/L)

LDL-C, low density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; TG, plasma triglycerides; N/A, not applicable; MLCD, moderate low carbohydrate diet; LFD, low fat diet




Figure S1: Funnel plot of the mean LDL-C differences (mmol/L) between CRD and LFD across trials (n=8)

MD - Mean Difference of LDL-C (mmol/L) between CRD vs LFD; SE (MD) - Standard Error of the MD

LDL-C, low density lipoprotein cholesterol; CRD, carbohydrate restricted diet; LFD, low fat diet






Figure S2: Funnel plot of the mean HDL-C differences (mmol/L) between CRD and LFD across trials (n=8)

HDL-C, high density lipoprotein cholesterol; CRD, carbohydrate restricted diet; LFD, low fat diet





MD - Mean Difference of TG (mmol/L) between CRD vs LFD; SE (MD) - Standard Error of the MD TG, plasma triglycerides; CRD, carbohydrate restricted diet; LFD, low fat diet